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GUTHRIE CARDS IN SCOTLAND: ETHICAL, LEGAL AND  
SOCIAL ISSUES 
 
 
EXECUTIVE SUMMARY 
 
This report considers the ethical, legal and social issues surrounding the existence, 
continued storage and future uses of the newborn screening collection held in 
Scotland (also known as the Guthrie card collection). The report was written over a 
four year period, 2009-2013, during which time earlier drafts of the report ensured 
that Guthrie Cards were included in the developing governance regime for 
biomedical collections within Scotland.  This final version is an account of 
developments as of April 2013 and involves an evaluation of the current 
arrangements as far as this is possible in a fast-moving field. The report also serves 
as a platform for future dialogue and development in light of wider social and 
international changes that are occurring, most notably in terms of the growing role for 
empowered citizens to contribute to, and benefit from, the future direction of health-
related research.  
 
The Scottish Guthrie card collection began in 1965 and now contains more than 2.5 
million cards which include blood/DNA samples and personal information relating to 
children born in Scotland since the inception of the collection until the present day. 
Numerous purposes are possible with respect to this collection but there is no 
dedicated legal framework that applies to it. Accordingly, this report approaches the 
resolution of the ethical and social issues from first principles, acknowledging the 
potential value of the resource while considering areas of law that might apply to it. 
Matters are complicated by the long-term nature of the collection – historically and 
into the future – whereby social attitudes and governance frameworks have changed 
over time and might change again in years to come. The prospect of the Guthrie 
collection being seen as a “de facto DNA database” means that these issues require 
on-going attention. Challenges in other countries such as Australia, Ireland, New 
Zealand and the United States with respect to similar newborn screening collections 
have demonstrated that a failure to address the issues appropriately and in a timely 
fashion can have very serious consequences, including destruction of whole 
collections in some cases. Such an outcome is not, however, inevitable. Scotland 
can learn much from the experience in other countries and this report highlights 
some of the pertinent lessons. 
 
The report argues that a robust, flexible and adaptive system is required to govern 
the Scottish Guthrie card collection. This must remain fit-for-purpose over time and 
must strike a delicate balance between maximising the value of the collection as a 
public resource to be managed for the public good while minimising the risks to 
individuals whose samples and data are held as part of the collection. While much 
attention has been paid to governance arrangements in the last four years, current 
practices could be improved further towards an optimal governance system for the 
collection and which would strike the appropriate balance of interests.  
 
The report details options for consideration as to how practices could be improved. In 
some cases it makes specific recommendations for action; in others, it identifies 
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opportunities for future dialogue about this and other biomedical collections. It is 
argued that public engagement should be undertaken in the development, 
implementation and on-going operation of policies with respect to the collection and 
potential and future uses.  
 
The report covers the following areas: 
 
Legal basis: The legal basis for the collection in Scotland is not captured in any 
single piece of legislation governing its existence. The position is complicated by the 
fact that the collection contains both personal information and DNA samples – the 
complicating factor is that separate legal regimes apply to data and tissue. While in 
England the equivalent collection appears to be treated as ‘tissue’, and is therefore 
regulated under the Human Tissue Act 2004 (HTA 2004), this Act does not, in the 
main, apply in Scotland and there is no equivalent legal regime. The one notable 
area of overlap between the two countries is, however, section 45 of the HTA 2004 
which does apply in Scotland. This section creates a criminal offence for non-
consensual DNA analysis. Unlike England, evidence in Scotland suggests that the 
entire collection is treated as part of the medical record and therefore is ‘data’ and 
subject to the provisions of the Data Protection Act 1998. It is recommended that for 
the avoidance of doubt and to ensure effective and robust protection of individual 
interests, the Guthrie collection in Scotland should be treated as both information and 
tissue for the purposes of legal governance. In addition, all practices with respect to 
the collection must be tested for human rights compliance. Any governance regime 
should reflect examples of ‘best practice’ from data and tissue regulation regimes 
while at the same time adopting a mechanism of proportionate governance, that is – 
a system of oversight and control that is proportionate to the risks involved and the 
benefits that can be achieved and which does not create undue regulatory burden on 
legitimate uses of the collection.  
 
Consent and anonymisation: Both consent and anonymisation are legal and ethical 
mechanisms used to protect and respect individuals and are accordingly of 
considerable importance. However, neither approach is a complete solution to 
challenges faced by large-scale, long-term biomedical collections. Each measure has 
limitations when considering how to strike the balance between individual rights and 
the pursuit of the public good. Close scrutiny is required of procedures both as to 
recruitment and withdrawal from the collection as well as to the role of anonymisation 
in legitimating research use. Although the law does not require it, consideration 
should be given to whether explicit consent should be obtained from people whose 
information and samples are held in the collection. Consideration should also be 
given to the details of an effective opt-out system, and whether mature minors should 
be allowed to opt-out. Other issues that requires attention are whether ‘consent for 
consent’ should be sought to facilitate research access, and whether consent should 
be sought from individuals if access is contemplated for non-healthcare purposes. As 
a minimum, there should be clear, transparent and accessible information about the 
collection, its uses and operation arrangements and mechanisms for citizens to 
enquire about its operation. It is important that a regular Privacy Impact Assessment 
be carried out on the operation and use of the resource. 
 
Access and storage: The growing awareness of the value of the Guthrie collection 
as an important potential resource for genetic and other forms of health-related 
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research means that access policies and procedures require priority and on-going 
attention. Moreover, the prospect of non-health related access, such as by the police, 
necessitates robust measures to protect individual interests. In light of the provisions 
of the Data Protection Act and human rights considerations, those responsible for the 
collection must also clearly define the purposes of the collection and link these to 
justifiable periods of retention. The appropriateness of the physical environment in 
which the collection is held and the way in which it is archived must be kept under 
regular review. It is recommended that a clear, robust and transparent and publicly 
available access policy should be operated; this should include guidance for decision 
makers on relevant factors to be taken into account when contemplating 
access/research requests. A written protocol for the release of samples and 
information to the police should be developed and should be publicly available. 
Personnel within the NHS should act as gatekeepers with respect to access requests 
and most notably and ideally Caldicott Guardians – as those persons responsible for 
patient confidentiality within the NHS - should be involved in the decision-making 
processes. Access policies must not only be transparent and easily intelligible, but 
these must also be kept under regular review and augmented with periodic updates 
on the kinds of uses of the collection that have been granted. Policies and 
procedures regarding feedback of information to individual citizens should be 
developed. 
 
Governance: Good governance of biomedical collections is essential and 
procedures must apply to all aspects of the resource from initial taking of consent 
and samples, to storage, quality assurance, access, networking, feedback and 
contingency planning. The relationship between:  
 
 The Southern General Hospital (SGH) in Glasgow (as custodian of the 
national resource for the first two years; archival storage thereafter)  
 NHS Greater Glasgow and Clyde Health Board (as responsible authority for 
SGH and the historic collection),  
 Healthcare Improvement Scotland (as the national inspectorate body for 
quality care and services), and  
 NHS Research Scotland (as the national strategic organisation),  
 
needs to be clarified, especially with respect to lines of accountability. The role of 
advisory and monitoring bodies also requires exploration, as does the input of the 
Caldicott Guardians. Reflecting the recommendations in the previous section, robust 
and transparent policies and governance mechanisms should be maintained and 
regularly reviewed. Relevant governance bodies should deploy reflexive governance 
whereby they engage in mutual learning about developments involving the resource 
and remain responsive to future challenges.  
 
Public attitudes and engagement: There is a lack of research in the UK generally 
and Scotland in particular on public and professional attitudes to the storage and 
further use of newborn blood collections.  Research conducted elsewhere suggests 
that although there is majority support for storage and appropriate, well-governed 
use, there are concerns about access, consent and the provision of information. 
Effective governance should be based on a sound empirical knowledge of public 
views and a programme of public engagement to ensure that governance 
arrangements are socially acceptable and ethically robust now and into the future.  
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Future Considerations: The transformative potential of biomedical collections for 
individual, local and global health is exponential. Scientific and technological 
advances mean that the possible future uses of the Guthrie collection are constantly 
changing and these no longer depend only on developments in the health sector – 
cloud computing and mobile applications mean that these valuable resources can be 
enriched and shared in ways never before contemplated. This also raises the 
possibility of a far more engaged role for the citizen interested in contributing to and 
influencing the future direction of research. While some of the more speculative 
possibilities are beyond the scope of this report, the fact that these can be foreseen 
makes it all the more important that Scotland develop a long-term, robust, responsive 
and imaginative approach to the management of its biomedical collections.  
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CHAPTER 1 - INTRODUCTION 
 
1.1 This report explores the ethical, legal and social issues surrounding the 
existence, continued storage and future uses of the Guthrie cards collection held in 
Scotland. The report has been prepared by Professor Graeme Laurie1 and Dr 
Kathryn Hunter2 under the auspices of the School of Law, University of Edinburgh, 
and includes a chapter on public attitudes and engagement from Professor Sarah 
Cunningham-Burley3, Centre for Population Health Sciences, University of 
Edinburgh.  
 
1.2 The evidence-base for this report has been developed from a literature review 
of pertinent legal and sociological materials; from an analysis of existing guidance 
and relevant documentation; from a comparative exploration of practices in other 
countries, and through discussions with key stakeholders, including the custodians of 
the collection. In the course of research the following persons and bodies were 
consulted: Mr David Aitken, Director and Ms Joan MacKenzie, Screening Co-
ordinator, The Scottish Newborn Screening Laboratory; Mr David Edward, the Human 
Tissue Authority; Ms Patricia Ruddy, Information Services Division, NHS National 
Services Scotland; Ms Christine Cavanagh, Programme Manager, UK Newborn 
Screening Programme Centre; Dr Deirdre Madden, Senior Lecturer in Law, 
University College Cork, Professor James Chalmers, Glasgow Law School; Mr 
Gerard Porter, Edinburgh Law School; and Dr Mark Taylor & Ms Jessica Wright, 
Sheffield Law School, respectively Principal Investigator and Research Coordinator 
of the European Commission Privileged project.4 We are grateful to all parties for 
their time and contributions, including participants in a roundtable discussion on 21 
January 2010 on an earlier draft of this report. Before and since then we have 
benefited from input from colleagues in Scottish Government – Gill Clark, Craig 
Gilbert and Vivian Leacock – who have worked with us over the years as governance 
arrangements within Scotland have developed. The inspiration for this work came 
from Dr Rosalind Skinner, Principal Medical Officer, Scottish Government (2009).  
 
1.3 The Scottish Guthrie card collection began in 1965 and now contains more 
than 2.5 million cards which include blood/DNA samples and personal information 
relating to children born in Scotland since the inception of the collection until the 
present day. Numerous purposes are possible with respect to this collection but there 
is no dedicated legal framework that applies to it and therefore the resolution of 
social and ethical arising from its continued retention and future use require careful 
attention. Matters are complicated by the long-term nature of the collection – 
historically and into the future – whereby social attitudes and regulatory frameworks 
                                            
1 Professor of Medical Jurisprudence and Founding Director of the JK Mason Institute for Medicine, 
Life Science and the Law, School of Law, University of Edinburgh. Research for the report began 
while Laurie was Director of AHRC/SCRIPT, a law and technology research centre based in 
Edinburgh Law School and sponsored by the Arts and Humanities Research Council (2002-2012). 
2 Dr Hunter was Research Manager for AHRC/SCRIPT at the time research for this report began and 
subsequently held the post of Senior Lecturer in Law at Northumbria University.   
3 Professor of Medical and Family Sociology, Head of School of Molecular, Genetic and Population 
Health Sciences, University of Edinburgh. 
4 The EC Privileged Project examines privacy in law, ethics and genetic data.   See: 
http://www.privileged.group.shef.ac.uk/ 
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have changed over time and might change again in years to come. The prospect of 
the Guthrie collection being considered as a “de facto DNA database”5 means that 
these issues require on-going attention. Equally, as the transformative potential of 
biomedical collections grows at an exponential rate – bringing potential changes for 
health and well-being at the individual, local and global level through networked 
sharing of resources and data – the need to institute robust and flexible governance 
mechanisms has never been greater. These must perform the dual role of protecting 
the personal interests of people whose samples and data form the basis of the 
collection while also responsibly promoting legitimate uses of the collection as a 
valuable research resource that can realise the potential that they hold.  
 
1.4 This report argues that a robust, flexible and adaptive system is required to 
govern the collection and deliver on these dual aims. This must remain fit-for-purpose 
over time and must strike a delicate balance between maximising the value of the 
collection as a public resource to be managed for the public good while minimising 
the risks to individuals whose samples and data are held as part of the collection. 
Evidence suggests that current practices could be improved towards an optimal 
governance system for the collection and which would strike the appropriate balance 
of interests. An important feature of this system would be its ability to engage with 
citizens on issues about how the resource in managed and run, including future 
dynamic ways that people can contribute to the resource and benefit from it.  
 
1.5 The legal landscape is complicated because the collection contains both 
personal information and DNA samples and the law treats information and tissues 
differently. Nonetheless, there is evidence that the collection is treated as part of the 
health record in Scotland, making it subject primarily to data protection legislation; 
this is in keeping with recent human rights pronouncements about how DNA samples 
should be treated and suggests an obvious regulatory framework. A first question to 
address is the legal position with respect to the collection. Thereafter, even if it is the 
case that data protection is the primary legal concern, careful and sensitive exercises 
of judgment will have to made about granting access to, and allowing use of the 
resource. Governance arrangements must be robust and inspire confidence. Our 
work on public engagement has informed the recommendations on what good 
governance might look like in order to deliver these objectives.   
 
1.6 The report details options for consideration as to how practices could be 
improved. In some cases it makes specific recommendations for action; in others, it 
identifies opportunities for future dialogue about this and other biomedical collections. 
It is argued that public engagement should be undertaken in the development, 
implementation and on-going operation of policies with respect to the collection and 
potential and future uses.  
 
1.7 The remainder of this report is organised as follows:  
 
Chapter 2 outlines current practice and the challenges associated with the collection, 
especially in light of recent experiences in other countries involving the management 
of similar collections.  
                                            
5 Genewatch, ‘Keeping blood spots from newborn babies’, January 2006, available at: 
http://www.genewatch.org/pub-507666 
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Chapter 3 details that core considerations for this report, that is, the factors that must 
be taken into account in delivering an appropriate governance mechanism and when 
balancing the range of interests at stake.  
Chapter 4 explores the legal basis for the collection  
Chapter 5 examines issues related to consent and anonymisation 
Chapter 6 is concerned with matters of storage and access 
Chapter 7 addresses governance 
Chapter 8 considers public attitudes and the role of public engagement in addressing 
the range of issues identified  
Chapter 9 concludes with a summary of questions for consideration and offers 
recommendations on how various challenges could be met as well as opportunities 
for dialogue about the future direction of biomedical collections.      
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CHAPTER 2 - CURRENT PRACTICE & CURRENT ISSUES  
 
2.1 This chapter outlines current practice with respect to the Guthrie collection and 
asks key questions about the legal, ethical and social issues arising from that 
practice.  Subsequent chapters will address each of these questions in turn. The 
discussion is set against the international scene from which Scotland has much to 
learn.  
 
Key questions are: 
 
 Is it lawful to continue to hold the collection when consent has not been 
obtained from the majority of people whose cards are kept? Which laws 
apply to the collection, who is responsible, and what are their 
obligations? 
 
 Should specific consent be sought from all persons whose blood spots 
and data are held as part of the collection? What are the arguments for 
and against this approach? What does the law and good practice 
require? What are the alternatives? 
 
 Can the collection be kept and used if the cards are anonymised? Is it 
possible or practical to do so? What are the pros and cons of 
anonymisation? 
 
 What kinds of uses should the collection be put to and which are lawful? 
Should access be allowed for health research? What about non-health 
research? What is the position about future requests about police 
access and access by commercial companies? 
 
 Who is legally liable if things go wrong?  Can existing oversight bodies 
in Scotland assist with the governance challenges of the Guthrie 
collection? 
 
 What do the public think about the Guthrie collection? How far, and how, 
should public opinion shape the use of the collection over time? Is a 
public education campaign needed? How could this be achieved?  
 
 Can lessons be learned from other countries or other biomedical 
collections?  
 
Current practice 
2.2 The Scottish collection of Guthrie Cards was started in 1965.  Between 1965 
and 2005 (when the current  computerised database was introduced) 2.5 million 
cards were collected. New cards are initially stored in chronological order at the 
Southern General Hospital (SGH), Glasgow. Cards over two years old are then kept 
in secured  document storage at optimum temperature and humidity. All of this is 
done under the auspices of Greater Glasgow and Clyde Health Board. Thus, unlike 
the position in the rest of the United Kingdom, one entity is primarily responsible 
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for the management and governance of the collection. This brings 
considerable advantages in terms of consistency of policies and streamlining 
of procedures as well as clear lines of legal responsibility. However, this 
custodian of the collection must interact with a number of other local and national 
bodies in ways that can leave lines of accountability unclear. For example, SGH 
operates within NHS Greater Glasgow and Clyde Health Board, and both in turn are 
subject to oversight by Healthcare Improvement Scotland (HIS) as the national 
inspectorate body for quality care and services.6 Furthermore, NHS Research 
Scotland was established in 2009 in order to ensure that NHS Scotland provides the 
best possible environment to support health research.7 NHS Research Scotland has 
issued National Guiding Principles for Governance of NHSScotland Tissue for 
Research and these principles are monitored by the Accreditation Scheme for the 
Collection and Storage of NHS Tissue in Scotland, operated by Healthcare 
Improvement Scotland.8 All Scottish biomedical collections – known as 
biorepositories – must adhere to these Principles. More details are required, 
however, on what happens if something goes wrong. Boards are accredited by 
Healthcare Improvement Scotland and therefore accountable for their practices, but 
the position on sanctions could be more transparent. Similarly, the possible sanction 
that a Board might impose on a biorepository operating under its auspices is also 
unclear.  
 
2.3 As stated, for the first two years the Guthrie collection is held and maintained 
by the Scottish Newborn Screening Laboratory within SGH. This is a National 
Specialist Service commissioned and funded by the National Services Division (NSD) 
and in turn this is a division of NHS National Services Scotland (NSS).9 Additionally, 
the collection is subject to guidelines and policies issued by both the UK 
National Screening Committee10 and the UK National Screening Programme 
Centre,11 albeit that each part of the UK determines when, and how, to put the 
policies into practice.12 This further complicates the chains of accountability. 
 
2.4 Since 2005, when a new card was introduced in Scotland, the blood spots and 
the personal information have been separated as soon as they reach the Glasgow 
laboratory, and the personal information has been entered in a database. Both parts 
of the card (bloodspot and personal information) are bar coded, which means 
that the cards are not irreversibly anonymised. This has implications for 
personal privacy.  
 
                                            
6 http://www.healthcareimprovementscotland.org/ (established 1 April 2011).  
7 http://nrs.mtcserver8.com/ (last visited 8 April 2013). For the strategy see: “Investing in 
Research|Improving Health: The Research Strategy for Health and Healthcare” (2009), available at - 
http://www.nhsresearchscotland.org.uk/cms/documents/CSO%20Investinng%20in%20Research%20-
%20Improving%20Health.pdf  
8 For details of the Accreditation Scheme (2011), see 
http://www.sehd.scot.nhs.uk/cmo/CMO(2011)07.pdf. Note, Para 4 of the Scheme makes it explicit that 
it extends to the Guthrie card collection.  
9 NSS is a non-departmental public body. As such, it is subject to Freedom of Information requests 
and applications for judicial review of its policies and decisions. 
10 http://www.screening.nhs.uk/about 
11 http://newbornbloodspot.screening.nhs.uk/programmecentre 
12 http://www.screening.nhs.uk/policyreview 
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2.5 With the exception of cards from 2000-2005, cards already stored have not 
been catalogued. As the old cards did not permit separation of the blood spots from 
the data, personal information and the blood samples are kept together. In 2007, the 
laboratory introduced a policy whereby new cards are kept at -20C degrees for two 
years and then moved and stored in a temperature controlled environment thereafter. 
These observations have implications for security, quality assurance procedures, 
data management procedures and, ultimately, effective and protective use of the 
resource.  
  
2.6 From 1965 to 2003, consent to inclusion in the Guthrie collection was 
‘presumed’, and parents were not told that the cards were to be kept.  Since 2003, 
however, written consent has been sought from parents.13 Currently, parents of 
newborn babies in Scotland are offered the opportunity to have their baby screened 
for five conditions: Phenylketonuria (PKU), Congenital Hypothyroidism, Cystic 
Fibrosis, Medium Chain Acyl - CoA Dehydrogenase Deficiency (MCADD) and Sickle 
Cell Disorders (SCD). The consent form in Scotland allows parents to choose to have 
their babies screened for individual tests, all tests, or none of the tests.  Thus, while 
current practice is based on a model that aspires to “informed consent”, the 
majority of the collection is held without any such consent.  
 
2.7 If parents choose to have their baby screened for one or more of the tests, the 
newborn blood spot card is retained, in the first instance, for a 12-month testing 
period, so that tests may be repeated if necessary.14 Scottish practice on initial 
retention is different from the practice in England where newborn blood spot cards 
are retained for a minimum of 5 years, in keeping with the UK Newborn Screening 
Programme Centre’s Code of Practice for the Retention and Use of Residual Blood 
Spots.15 
 
2.8 In Scotland, at the time initial consent for the tests is requested (5-7 days after 
birth), parents are also asked to provide permission to allow the blood spot card to be 
stored beyond the 12-month testing period and the information leaflet states: “Left 
over blood spots can also be used anonymously for other monitoring and laboratory 
purposes such as comparing different screening methods and developing new tests. 
Occasionally it is necessary to use identifiable specimens, in which case the parents’ 
permission would always be sought. If you do not want the stored blood spot card to 
be used for research, please ask the midwife to write ‘no research’ in the comments 
box on the blood spot card.”16 It is confirmed that parents are not asked when 
research is done anonymously, but will be approached if they or their baby can be 
identified. The wording of the leaflet raises two important issues: (1) are parents 
being invited actively to consent to retention or to opt-out of retention? This is 
                                            
13 This was initiated because Scotland started screening for Cystic Fibrosis at that time.  The CF test 
is done in two stages; the second stage involves DNA analysis, which was a departure from the kinds 
of tests that were done previously.  Due to sensitivity around DNA testing, explicit consent was 
introduced for newborn blood spot screening. 
14 “Your Guide to Newborn Screening Tests” (2012): 
http://www.healthscotland.com/documents/4258.aspx  
15 Newborn blood spot screening in the UK – Policies and Standards, April 2005.  ISBN 0955013801, 
available at: http://newbornbloodspot.screening.nhs.uk/cms.php?folder=2547. This document remains 
current and embodies as Code of Practice on how the retained Guthrie cards will be used, see: 
http://newbornbloodspot.screening.nhs.uk/public#13 
16 Your Guide to Newborn Screening Tests, p20, n14 above.  
11 
important for parental expectations and also practically in terms of what will be 
done in the event that the comments box is left blank. Moreover, does a non-
response indicate meaningful consent or is it mere silence? (2) The informed 
nature of any apparent assent is very limited. The expression “[m]onitoring and 
laboratory purposes” suggests a narrow range of use and yet the potential 
research uses of biomedical collections such of these is extensive. This raises 
issues for consent and governance and we explore these later in the respective 
chapters.  
 
2.9 If parents do not agree to allow the retention of the blood spot card beyond the 
12-month testing period, the card is destroyed;17 otherwise, parents can agree to 
continued retention of their child’s card either in the health interests of the child only, 
or for research purposes. Retention after the initial 12-month period becomes de 
facto indefinite retention, although operational practice is to respect 
subsequent wishes for destruction.18  The NHS Research Scotland Guiding 
Principles make it clear that any biorepository that receives a written request for 
destruction of samples and data must comply so far as this is practicably, i.e. – 
sometime data might no longer be within the control of the biorepository managers.19  
 
2.10 In governance terms, the Scottish collection is subject to the guidance of the 
UK Newborn Screening Programme Centre on issues such as quality assurance and 
performance management and the UK National Screening Committee which advises 
on screening policy. The Greater Glasgow & Clyde Health Board has an independent 
Biorepository Governance Board that considers operational matters for the Guthrie 
card collection and this includes requests for access. Primary responsibility for 
receiving recommendations in this report must, accordingly, rest there. As a first step, 
however, the Board must address issues of transparency.20 This must be an 
immediate priority given the extensive issues to be addressed – and lessons from 
other countries which have arisen in large part because of lack of transparency (see 
further below).   
 
Current issues 
Is the collection lawful? 
2.11 The legal status of the Guthrie card collection in Scotland has never been 
tested in court nor addressed directly by Parliament. Current arrangements operate 
on a complex 'soft law' hybrid approach whereby the UK Newborn Screening 
Programme Centre has issued a Code of Practice (2005) and Standards Guidelines 
(2008;21 2013 Consultation report22) but leaves regions to decide on best practice 
                                            
17 Procedures exist to record parental wishes about use/non-use and parents who express a wish that 
retention does not continue after 12-months are re-contacted to confirm this. 
18 Pers. comm. 
19 Available on request from Chief Scientist Office.  
20 http://www.nhsggc.org.uk/content/default.asp?page=s1685. 
21 UK Newborn Screening Programme Centre, Standards and Guidelines for Newborn Blood Spot 
Screening, August 2008. 
22 UK Newborn Screening Programme Centre, Consultation on the newborn blood spot screening 
standards mapped to the generic standards framework: 20th December 2012 – 4th February 2013 - 
Consultation report, March 2013: http://newbornbloodspot.screening.nhs.uk/standards-consultation-
2012-13. 
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independently. This has given rise to disparate approaches to the Guthrie collections 
around the UK. For example, information leaflets to parents are not standardised and 
the range of parental options differ between the countries (i.e. Scotland gives a one-
year retention option while this is not available in England). Furthermore, while 
England has carried out a public consultation,23 no specific public engagement has 
thus far taken place in Scotland.   
 
2.12 Furthermore, the legal landscape in Scotland can at times differ from the rest 
of the United Kingdom. This is particularly true with respect to human tissues 
because the Human Tissue Act 2004 does not, with a notable exception, extend to 
Scotland. Similarly, freedom of information requests are dealt with under specific 
Scottish legislation.24 In contrast, the Data Protection Act 1998 is a UK-wide statute 
with no Scottish variations. Thus, to the extent that the Scottish collection involves 
both human samples and personal data the legal framework is a complicated 
network of domestic and UK-wide provisions. From a policy and procedural 
perspective, however, Scotland has a wide degree of autonomy and discretion in its 
approach to storage and use of the collection. We discuss the legal status of the 
collection in Chapter 4. 
 
Is informed consent to the collection required? 
2.13 The Scottish collection began at a time when medical matters were subject to 
a lot less oversight than happens today. In particular, consent from patients or 
relatives was not the norm, as it has since become. Consent to Guthrie card 
collection, storage and use became the norm in Scotland in 2003 for all newborns 
and is now routine; this nonetheless means that the majority of the existing collection 
is held without explicit consent from the persons to whom it relates or from their 
parents if they are still children. If the continued holding of the collection were to be 
contingent on explicit consent this would raise a plethora of ethical, practical and 
economic problems. But is this what the law or good practice requires? Would it be 
practical or desirable? We discuss the role of consent in Chapter 5.     
 
What can the collection be used for? 
2.14 This report comes at a time when there is both increased interest in the value 
of public collections such as Guthrie cards and well as increased scrutiny of their 
very existence, let alone their continued storage and use. As interest in use grows, 
so too does the number of associated ethical, legal and social issues and potential 
challenges. Whereas the original purposes for the taking of samples is, and always 
has been, determinedly the health interests of the child, Guthrie collections around 
the world can and are put to an increasingly wider range of purposes and uses going 
beyond individual health interests; among others, these extend to societal health 
interests and other so-called public interests such as (health) research more 
                                            
23 In March 2004, a public consultation on “Telling parents about the heel-prick test” was undertaken 
by Stewart, Hargreaves and Oliver, report available at: 
http://newbornbloodspot.screening.nhs.uk/cms.php?folder=2488; another consultation was held in 
2005 on the “Storage and use of newborn babies blood spot cards: a public consultation” (Oliver, S, 
Stewart, R, Hargreaves, K and Dezateux, C.  London: Social Science Research Unit, Institute of 
Education, University of London); however, the report of this consultation is not yet available. 
24 Freedom of Information (Scotland) Act 2002. In the rest of the UK the law is contained in the 
Freedom of information Act 2000. 
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generally, and the detection and prosecution of crime. Police access has been 
granted in the past, for example, for identification of deceased persons (see Chapter 
6 below). Recently, there has been an increase in requests from research groups 
interested in gaining access to cards in the Scottish collection. The legitimacy and 
lawfulness of granting access for a wide range of purposes or uses is discussed in 
Chapter 6 below. 
 
Who is responsible for the collection and what does this mean? 
 
2.15 Scotland has a robust mechanism of research governance and ethical 
approval but the governance framework for the collection is complex and multi-
levelled. We have seen above the arrangements for custodianship of the Guthrie 
card resource and how this implicates local, regional and national bodies. Matters are 
complicated further as the transformative potential of such a biomedical collection 
becomes stronger. For example, it is well-recognised that the full promise of these 
resources will only be realised through national and international networks of data 
and sample sharing.25 In governance terms, this means that no collection stands 
alone and those seeking access must engagement with a range of mechanisms. For 
example, as well as a sophisticated system of local and multi-centre research ethics 
committees, the Privacy Advisory Committee (PAC) operates in Scotland under the 
auspices of NHS National Services Scotland (NSS) to advise the Information  
Services Division of NHS Scotland (ISD) and National Records of Scotland (NRS) on 
requests for research access to data in the Scottish Medical Record without explicit 
consent and/or if linkage of data which might pose an increased risk to patient 
privacy. As a body operating under NSS (in the same way as the National Screening 
Laboratory) there may be a role for PAC in delivering good governance for the 
Guthrie Card collection. That said, the remit of PAC does not extend to access to 
samples (as opposed to patient data) nor does it cover resources held exclusively 
within health boards. It would only be in circumstances where there was a proposal 
to link Guthrie data with ISD or NRS data that PAC would have a say. This suggests 
a fragmented regulatory landscape. At the international level, questions arise about 
whether data and samples can or should be sent abroad, under what conditions, and 
with which responsibilities. We discuss possible governance mechanisms in Chapter 
7 below.  
 
What does the public think? Should the public be involved more? 
2.16 Public perceptions and attitudes have an important and growing role to play in 
the development of robust and acceptable policies within the healthcare setting. 
Whereas once consent was the exception rather than the rule, today the converse is 
true. Moreover, law and public perception do not necessarily coincide so that what is 
lawful might nonetheless be unacceptable to a majority or vocal minority of the 
Scottish public. There is no need to rehearse the sensitivities that surround the 
(mis)handling of patient information or samples, but equally it is essential to consider 
whether and how public opinions can inform health policies and the operation of 
biomedical resources now and in the future. We discuss public attitudes in Chapter 8 
below. 
 
                                            
25 See, for example, J. Kaye, ‘From single biobanks to international networks: Developing e-
governance’ (2011) 130(3) Human Genetics 377-382.  
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What lessons can we learn from other countries? 
 
 2.17 The practice of retention of newborn screening cards has been commonplace 
in many countries since the 1960s. The phenomenon began at a time when social 
and ethical expectations were very different to those of today. These have changed 
considerably over time. Furthermore, the potential value of these collections has also 
grown over the decades both with advances in genetic analysis and also with the 
prospect of effective linkage to medical and other records.26 This means that the 
nature and balance of the sum total of interests has shifted – as the public interest in 
these collections has increased, so too has the interest of private citizens in the 
secure and robust retention of their data and samples. A failure to appreciate and 
respond to these changing social circumstances has left the status of many 
collections in a legal and ethical limbo.27 In some cases, a failure to engage families 
and publics about the existence and possible uses of such resources has resulted in 
numerous high-profile destructions of entire collections. 
 
2.18 The most high-profile example of destruction comes from Texas. The state of 
Texas collected 5.3 million card samples from children between 2002 and 2009 and 
these were used, among other things, for anonymised research in 8350 cases and 
always with ethics committee approval. Research projects, including investigations 
into genetic causes of deafness, were published on the Department of State Health 
Service website. In a very small number of cases – 200 out of 5.3 million – 
identifiable research was carried out but this was always with the consent of parents. 
Notwithstanding these arrangements, the Texas Civil Rights Project brought a class 
action against the state of Texas for alleged violation of federal constitutional rights, 
notably that the unconsented use was an illegal search and seizure.28 The state lost 
its motion to dismiss, i.e. – the court held that there were legitimate legal interests in 
play – and the state finally settled out of court before any action was given a full 
hearing.29 The state agreed to destruction of the entire collection, despite its 
recognised research value. Any hope of reprieve was lost when it emerged that 800 
samples had been sent to a federal Armed Forces mitochondrial database to assist 
in the ethnicity categorisation of remains of missing persons. Crucially, freedom of 
information documentation revealed that although the state had contemplated 
publishing the details of this agreement, it decided not to do so because of concerns 
about public reaction. This significant failure in transparency signalled the final end of 
the resource.30 Similar law suits have been brought in the US state of Minnesota31 
                                            
26 J. Couzin-Frankel, „Newborn blood collections. Science gold mine, ethical minefield‟ (2009) 324 
(5924) Science 166-8 and J. Wilkinson, „Analysis of Guthrie cards could provide insight into 
epigenome at birth‟ (2012) 4(5) Epigenomics 480-1.  
27 See, M. Carmichael, „Newborn screening: a spot of trouble‟ (2011) 475 Nature 156-158, 
doi:10.1038/475156a, and M.H. Lewis, A. Goldenberg, R. Anderson, E. Rothwell and J. Botkin, „Blood 
samples: State laws regarding the retention and use of residual newborn screening blood samples‟ 
(2011) 127 Paediatrics 703-712. 
28 Beleno v Tex. Dept. of State Health Services, (2009); For commentary, see K. Drabiak-Syed, „Legal 
regulation of banking newborn blood spots for research: How Bearder and Beleno resolved the 
question of consent‟ (2011) 11 Houston Journal of Health Law and Policy 1-46. 
29 For selected docket material from the case and reference to the settlement agreement, see here: 
http://iucb.wordpress.com/2010/02/26/newborn-blood-spots-biobanks-the-law-research-ethics-in-the-
news/ 
30 For an account of the circumstances, see: 
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and in the Canadian province of British Columbia,32 both on grounds of alleged 
violation of privacy by retention and use of sample and data. There is no uniformity in 
North America as to the regulation of Guthrie collections.33 
 
2.19 It is important to note that these law suits only reveal that the legal status of 
newborn screening collections is unclear in the particular jurisdictions where the 
disputes have arisen. Thus, in the Minnesota example the Supreme Court 
recognised the lawfulness of the existence of the collection but noted that the 
applicable law restricted many uses to consent-only circumstances, e.g. for research. 
In the British Columbia (BC) situation, the validity of the legal basis for the plaintiff’s 
claims was in question and the government argued that there was no genuine issue 
for trial. The Supreme Court of the province held that there was no such genuine 
issue either with respect to the taking of the samples or their retention for medical 
purposes. The court suggested that, on an objective view, a reasonable person in the 
circumstances of the plaintiff would have consented to such storage.34 As to uses for 
medical research, this had happened on two occasions with the BC collection on an 
anomymised basis. Here the court did hold that there was a case to answer: “…it is 
the use of a sample for purposes other than promoting the health of the infant from 
whom it was obtained that raises a genuine issue for trial in this case.”35 However, 
because of the way that the case had been pled to the court, it was not possible for 
the judge to determine the issue. Instead, it recognised that a case could be made 
and gave the plaintiffs thirty days to amend their claim. To date, no subsequent 
action has been successfully brought.  
 
2.20 Similar concerns about the legal status of Guthrie collections have arisen in 
Europe. Despite the existence and operation of collections around the European 
Union, the Irish Health Service Executive issued a notice of destruction in 200936 
because it was concerned about breaches of European data protection legislation for 
want of explicit parental consent for retention and use of the resource. However, in a 
last minute reprieve, the Minister for Health issued a statement in March 2013 in 
which he announced a further review of the collection, and in particular an 
assessment of the legality of other European collections and the implications for 
Ireland. Minister James Reilly “…communicated his deep concern to the HSE that no 
action should be taken in relation to the destruction of Guthrie cards until an expert 
                                                                                                                                        
 http://www.genomicslawreport.com/index.php/2010/03/16/the-texas-newborn-bloodspot-saga-has-
reached-a-sad-and-preventable-conclusion/ 
31 S. Hu, ‘Minnesota Supreme Court hears whether the Genetic Privacy Act protects newborn blood 
spot samples obtained under the state's newborn screening statutes--Bearder v. State of Minnesota.’ 
(2012) 38(1) Am J Law Med 225-7. 
32 See L.D. (Guardian ad litem of) v. Provincial Health Services Authority (2011) BCSC 628. 
33 M.H. Lewis, A. Goldenberg, R. Anderson, E. Rothwell and J. Botkin, ‘State laws regarding the 
retention and use of residual newborn screening blood samples’ (2011) 127 Paediatrics 703-712. For 
an argument for harmonisation of guidance, see: B.L. Jr Therrell, W.H. Hannon, D.B. Jr Bailey, E.B. 
Goldman, J. Monaco, B. Norgaard-Pedersen, S.F. Terry, A. Johnson, and R.R. Howell, ‘Committee 
report: Considerations and recommendations for national guidance regarding the retention and use of 
residual dried blood spot specimens after newborn screening’ (2011) 13(7) Genetic Medicine 621-4. 
34 Note 32, at paras 51-55.  
35 Id., at para 58.  
36 See, R. McGreevey, “Calls for 'priceless resource' of heel prick test results to be saved”, The Irish 
Times, 5 February 2013, available at: http://www.irishtimes.com/news/health/calls-for-priceless-
resource-of-heel-prick-test-results-to-be-saved-1.1254279 
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group can meet and that the group considers how these cards could be archived and 
maintained in a manner that meets the data protection commissioner’s concerns”.37 
 
2.21 Part of the concerns in Ireland were motivated by development in New Zealand 
and Australia. For example, while in New Zealand the retention and use of the blood 
spot collection is authorised by law, any population research on samples older than 
June 2011 can only be done with explicit consent. Importantly, however, other kinds 
of research do not necessarily require consent so long as there is appropriate ethical 
approval.38 In Australia, the governance of collections is state-based albeit that there 
is no specific legislation in any single state and recommendations for national 
guidance have not been developed.39 In Victoria, a Review Committee recommended 
that consent be the basis for future collection and use,40 while in Western Australia 
police access to the Guthrie collection to investigate an alleged case of incest led to 
a policy of destruction of all cards older that two years.41  
 
2.22 The lessons to be learned for Scotland are: 
 
 The importance of determining the legal status of the collection 
 The need to determine current and future uses of the resource 
 The relative role and importance of consent in governing the collection
 The considerable value of transparency in all processes 
 The vital importance of public engagement in determining the future of the 
collection. 
 
2.23 The next chapter outlines the considerations which are in play in this discussion 
and offers a framework to approach the particular issues outlined above.  
                                            
37 See, M. Houston, “Reilly does U-turn ordering HSE not to destroy newborn blood samples - Heel 
prick cards to be retained until expert group reports”, The Irish Times, 26 March 2013, available at: 
http://www.irishtimes.com/news/health/reilly-does-u-turn-ordering-hse-not-to-destroy-newborn-blood-
samples-1.1338666. 
38 See Health and Disability Commissioner (Code of Health and Disability Services Consumers' 
Rights) Regulations 1996 (SR 1996/78), Right 7(10), and for a lay explanation The NZ National 
Screening Unit: http://www.nsu.govt.nz/current-nsu-programmes/2917.aspx. 
39 Australian Law Reform Commission, Essentially Yours: The Protection of Human Genetic 
Information in Australia (2003), chapter 19.   
40 Victorian Newborn Screening Review Committee, Final Report for the Minister for Health (2006), 
available at: https://www.privacy.vic.gov.au/privacy/web2.nsf/files/victorian-newborn-screening-review-
committee-final-report/$file/report_08_06.pdf 
41 See D.M. Bowman and D.M. Studdert, ‘Newborn screening cards: a legal quagmire’ (2011) 194(6) 
Medical Journal of Australia 319-322, at 319 quoting Office of the Victorian Privacy Commissioner, 
Submission to the Forensic Procedures Review Committee on its review of Part ID of the Crimes Act 
1914 (Cth). (2002) Melbourne: Privacy Victoria.     
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CHAPTER 3 - CORE CONSIDERATIONS FOR THIS REPORT: 
PERSONS, PURPOSES AND PROCEDURES  
 
 3.1 It is important to identify the core concerns associated with the collection, 
storage and use of Guthrie cards in Scotland in order to inform adequately the 
discussion and recommendations in this report and the future policies applied to the 
collection. We suggest that the core considerations relate to: Persons, Purposes and 
Procedures.  
 
Key questions to ask of the collection are: 
 
 Which persons are affected by the collection and how?  
 
 What purposes are envisaged for the collection, now and in the future, 
and how legitimate are these purposes?  
 
 What procedures are required to respect persons and to legitimate 
purposes? 
 
Key messages from this chapter are: 
 
1. It is essential to consider the full range of people affected by the 
collection. Different people might be affected in different ways and 
different legal rules might apply to them.  
 
2. It is essential to consider the full range of purposes for which the 
collection might be used, both now and in the future. Although a range 
of purposes might be justified, the case for each use must be clearly 
made.  The justifications must be all the stronger as the use becomes 
more about the public interest and less about each person’s health 
interest.  
 
3. It is essential that clear, transparent and robust policies are in place for 
every aspect of the collection from initial taking of consent and samples, 
to storage, quality assurance, access and contingency planning.   
 
DISCUSSION 
Persons 
3.2  We have already indicated that the long-term nature of this collection in 
Scotland and its prospective expansion raise particular issues and it may not be the 
case that a one-size-fits-all approach is possible or desirable. From the perspective 
of persons affected by their inclusion in the collection, we suggest that there are at 
least five (5) discrete categories of persons to consider. These are:  
 
1. Persons who are now adults and for whom consent was never given 
(1965-1997) 
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2. Persons who are still children but for whom consent was never given 
(1997-2003) 
3. Persons who are still children and whose parental consent has been given 
(2003-now) 
4. Persons who have died since the collection began 
5. Future persons and whether and how their samples should be obtained 
and retained. 
 
3.3 The relevance of this categorisation turns around the crucial date of 2003 
when informed consent procedures were introduced. It does not necessarily follow, 
however, that because consent is now obtained that it should be sought from all of 
those for whom consent was never sought or who might now be in a position to 
consent for themselves. The relevance of death is also legally significant, for 
example, because the requirements of the Data Protection Act 1998 do not apply to 
deceased persons (although the common law duty of confidence continues after 
death). Furthermore, as regards future persons it may be the case that current 
consent procedures can be improved. Overarchingly, while explicit consent might not 
be necessary or practicable, it is nonetheless important to offer an opt-out system for 
all who would choose it. This is now provided for by NHS Research Scotland 
National Guiding Principles for Governance of NHSScotland Tissue for Research. 
 
Purposes 
3.4 It is important to consider current and future purposes of the resource because 
legal and ethical legitimacy of the collection is framed around the purposes for which 
samples and taken, stored and used.42 Different purposes will have a different impact 
on different categories of persons. What, then, is the range of current purposes and 
what are future purposes likely reasonably to be? What possible impact might these 
various purposes have on different categories of persons and their interests? 
 
3.5 It is helpful to consider the range of purposes in the form of a series of 
concentric circles, with the individual and his or her health interests at the centre of 
that circle – indicating what should be the primary focus of our attention - and wider 
societal interests occupying the outer circles - indicating that as we move further 
away from the individual stronger justification of purposes is required.  
 
 
                                            
42 The UK Newborn Screening Programme Centre’s website sets out the various uses of the stored 
blood spots: 1. To monitor and improve the newborn screening programme; 2. To directly benefit 
individuals and their families; 3. To monitor the health of the general population; 4. To answer 
questions about specific health problems; 5. To develop new equipment and tests; 6. For police 
forensic work. See: http://newbornbloodspot.screening.nhs.uk/FAQs.  
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3.6 The list of current purposes includes: 
 
 the immediate health benefit of the child (PKU etc.) 
 
 the longer-term interests of individuals and their families (e.g. causes of 
infant or childhood death or disease; the identification of familial genetic 
conditions; the identification of deceased persons) 
 
 the monitoring and improvement of the newborn screening programme 
(i.e., for the interests of newborns and families generally) 
 
 the monitoring of the health of the general population (e.g. rates of HIV 
infection, genetic markers in childhood diseases etc). 
 
The list of possible future purposes includes: 
 
Figure 1:  
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 Health-related research generally (which might include linkage to other 
information leading to, or increasing the risk of, identifiability of specific 
individuals) 
 
 Non-health related research, e.g., proposals for access by insurers or 
employers (should this ever be contemplated) 
 
 Forensic police work: There are two broad purposes under this 
category: (i) the identification of dead or missing individuals, (ii) the 
detection and prosecution of crime.  
 
3.7 Factors which might complicate the issues surrounding these purposes 
include the prospect of access by those with commercial interests, e.g. research 
undertaken by large-scale pharmaceutical companies. While this is a reality, it could 
raise broader concerns. For example, some public attitude surveys suggest a degree 
of discomfort among some sectors of the public when public health resources are 
used to generate excessive private profit.43  
 
3.8 While the importance of an individual’s interests is fundamental, those 
interests, or indeed their individual rights, are rarely (if ever) absolute. That is, while 
individuals can claim certain rights, such as the right to respect for private life, it is 
often the case that exceptions exist and rights can be interfered with so long as just 
cause is shown. In the language of human rights, for example, interference with the 
individual’s right to respect for private life is justifiable if that interference is 
necessary, proportionate and is reasonably likely to further other legitimate social 
ends. These include: “...the interests of national security, public safety or the 
economic well-being of the country, for the prevention of disorder or crime, for the 
protection of health or morals, or for the protection of the rights and freedoms of 
others.”44 
 
3.9 The core lesson here from a legal perspective is that likely interferences with 
individual rights must be fully explained and justified. The same is true from an 
ethical perspective, viz, purposes, policies and procedures must be robust and 
defensible even if they are not necessarily accepted by all persons affected. 
Furthermore, for those persons who disapprove of particular purposes it is prudent, 
and indeed necessary, to offer an opt-out system which at the same time as 
respecting their individual choice does not necessarily undermine the public interest 
in the resource itself (see now the NHS Research Scotland Guiding Principles). 
 
 
 
 
 
                                            
43 G. Haddow, G. Laurie, S. Cunningham-Burley and K.G. Hunter, ‘Tackling community concerns 
about commercialisation and genetic research: A modest interdisciplinary proposal’ (2007) 64 Soc Sci 
& Med 272-282.  
44 See Article 8(1) and 8(2) of the European Convention on Human Rights as incorporated in the 
Human Rights Act 1998. 
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3.10 It is important to consider procedures because transparency, accountability 
and trust can, in large part, be built around well thought-through and well-executed 
processes for decision-making, quality assurance, governance and public 
engagement. Central to this is the value of Standard Operating Procedures (SOPs). 
Which exist? How fit for purpose are they? Which need to be introduced? Why and 
how?  
 
3.11 The UK Newborn Screening Programme Centre (UK NSPC) has a range of 
existing procedural documents covering many aspects related to initial taking and 
storage of blood spots. For example, these include information about communicating 
with parents, ensuring high quality blood spots, laboratory quality assurance 
guidelines and implementation and reporting guidance with respect to UK-wide 
policies on newborn screening.45 
 
3.12 In August 2008, the Centre produced updated Standards and Guidelines for 
Newborn Blood Spot Screening, and stated that: “Central to the development of 
policies are standards that underpin the performance management of the blood spot 
screening programme. Their purpose is to assure the quality of the screening 
process and ensure that babies who may have one of the conditions for which 
screening is offered receive timely medical treatment.”46 These were subject to a 
recent consultation exercise, the report on which was published in March 2013.47 133 
responses were received, including from parents, parent representative groups, 
health professionals and professional bodies. Scotland was included in the recent 
consultation.   
 
3.13 NHS Quality Improvement Scotland has developed Clinical Standards for 
Pregnancy and Newborn Screening (2005)48 reflecting the above and which require 
in particular that “All women/parents/carers receive clear information (written or in 
other formats) to help them to make an informed decision about newborn bloodspot 
screening” [Statement 4b].  
 
3.14 These procedures focus, rightly, on the health interests of each infant and the 
quality of the samples and data collected. As we have seen, however, longer-term 
storage for a wider range of purposes have different impacts. First and foremost, 
these impact on the quality of the consent that is obtained and the degree and quality 
of information given to parents. Both England and Scotland have documentation 
available to parents which mention (in superficial detail) the possibility of research but 
not the possibility of police access;49 and while the range of possible uses is 
contained in the UK NSPC 2005 Code of Practice and on its website, it is not entirely 
clear how well lines of communication between health professionals and parents join 
up in practice. The UK NSPC Health Professional Handbook 2012 details procedures 
                                            
45 See further: http://newbornbloodspot.screening.nhs.uk 
46 http://newbornbloodspot.screening.nhs.uk/standards#fileid10827 
47 Available at: http://newbornbloodspot.screening.nhs.uk/standards-consultation-2012-13 
48 Available at: 
http://www.healthcareimprovementscotland.org/previous_resources/standards/pregnancy_and_newbo
rn_screen.aspx 
49 See the leaflet on newborn blood spot screening at: 
http://newbornbloodspot.screening.nhs.uk/languages; and NHS Scotland, Your Guide to Newborn 
Screening Tests, available at:  http://www.healthscotland.com/uploads/documents/20214-
YourGuidetoNewbornScreeningTests.pdf 
Procedures
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to discuss and record decisions about research, but again makes no mention of 
police or commercial access/uses.50  Robust procedures can address this.  
 
3.15 More broadly, the contemplation of other purposes beyond individual health 
interests need both to be articulated and communicated clearly and to be handled 
appropriately. This turns on procedures with respect to access. In research terms, 
there already exist detailed governance frameworks within the health service which 
can be deployed to guide researchers in seeking access to the resource and which 
also could act as a safeguard for patient rights and interests. The NHS Research 
Scotland Guiding Principles mentioned in para 2.2 are a suitable locus for details on 
access terms and conditions.  
 
3.16 In police terms, it can matter very much whether the Guthrie collection is seen 
as part of the medical record in Scotland or is sui generis (of its own kind). Different 
procedures might apply depending on whether the request for access is to 
“information” or to a physical object (e.g. a blood sample).  Finally, as for future un-
contemplated requests for access – for example, non-health related research - clear 
procedures and lines of authority and accountability can help to ensure that these are 
dealt with timeously and appropriately and can provide decision-makers with 
guidance as to the relevant factors and considerations to be taken into account in 
making a final decision. A commitment to openness about these procedures and any 
uses that are made of the collection can also help to dispel concerns as well as 
facilitate an opt-out option for those who wish to use it.      
                                            
50 newbornbloodspot.screening.nhs.uk/getdata.php?id=10953 
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CHAPTER 4 – THE LEGAL BASIS OF THE COLLECTION  
 
Key questions addressed by this chapter are: 
 
 Is it lawful to continue to hold the collection when consent has not been 
obtained from the majority of people whose cards are kept?  
 
 Which laws apply to the collection, who is responsible, and what are 
their obligations? 
 
Key messages from this chapter are: 
 
 Different legal regimes govern the Guthrie collections in England and in 
Scotland.  In England, the collection would appear to be treated as 
‘tissue’, and therefore subject to the Human Tissue Act 2004. This Act 
does not apply to Scotland, with the notable exception of section 45 
(criminal offence of non-consensual DNA analysis).  In Scotland, the 
collection appears to be treated as part of the health/medical record and 
is, therefore, subject to the provisions of the Data Protection Act 1998, 
which must also be read with the common law of confidentiality. 
 
 The lawfulness of continued retention and use of the collection depends 
on compliance with the Data Protection Act 1998, the relevant provision 
of the Human Tissue Act 2004 (section 45), and the common law of 
confidentiality. Professional guidance and prior commitments made to 
the Scottish public might also constrain future retention and use.   
 
 For the avoidance of doubt and to protect the full range of individual 
interests at stake, the Guthrie collection should be treated as both 
personal information and human tissue for the purposes of robust 
governance.  
 
 Consent to use is not an absolute requirement of the law but should not 
be departed from lightly. 
 
 Anonymisation can remove some legal obligations but not all 
obligations; moreover, it is not a complete answer to the challenges 
thrown up by the collection. 
 
 Human rights are a consideration across all areas of law. All 
mechanisms, policies and procedures should be tested for human rights 
compliance.  
 
DISCUSSION 
4.1 The legal authority for the existence and continued retention of the Guthrie 
collection in Scotland is complicated. As an initial and broad consideration, all laws 
and practices must be viewed through the lens of human rights and all practices with 
respect to the collection must respect individuals’ human rights. When considering 
which specific laws might apply to the collection, there are practical and jurisdictional 
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variations within the United Kingdom which complicate the situation and the 
overarching influence of European law must also be considered. Practically, the 
cards contain both physical blood/DNA samples and personal information. We must 
therefore ask: is the blood spot collection itself a “thing” or information or both or 
something different altogether? This is not a trivial consideration. It matters very 
much how these collections are viewed because different legal regimes apply to 
information as opposed to tissues (and sometimes no specific laws apply at all).51 
 
4.2 Further complications arise when we compare the position in England and 
Scotland. Whereas in England blood samples would appear to be regarded as 
human tissue, and therefore covered by the Human Tissue Act 2004,52 in Scotland 
they appear to be treated primarily as medical records; that said, a single but 
important provision from the 2004 Act also applies in Scotland and must also be 
considered (see 4.26-4.32 below).   
 
4.3 For the purposes of discussion, then, we must consider whether the collection 
should be regarded as (a) information, (b) tissue, or (c) both. The pros and cons of 
each approach are considered below. All of this is subject to human rights 
considerations. 
 
The collection as information 
4.4 If the collection is seen as personal information, then the applicable laws are 
found, in the first instance, in the Data Protection Act 1998 which has application 
throughout the United Kingdom. The Act is the implementation by the UK 
government of the terms of the Data Protection Directive that is applicable across all 
27 member states.53 To the extent that the collection as a whole contains information 
relating to living persons, for example, names, addresses, medical and health data 
etc, and from which persons can be identifiable, then the provisions of the Data 
Protection Act 1998 apply to the storage and processing of these data. It is unclear, 
however, whether a sample such as that containing DNA is in itself also personal 
information for the purposes of these laws. On the one hand the Article 29 Working 
Party has observed that: 
 
Human tissue samples (like a blood sample) are themselves sources 
out of which biometric data are extracted, but they are not biometric 
data themselves (as for instance a pattern for fingerprints is biometric 
data, but the finger itself is not). Therefore the extraction of information 
from the samples is collection of personal data, to which the rules of the 
                                            
51 For comment on this fragmented approach to legal regulation of tissue and data, see G. Laurie and 
S.H.E. Harmon, ‘Through the thicket and across the divide: Successfully navigating the regulatory 
landscape in life sciences research’ in M Pickersgill and E Cloatre (eds), Knowledge, Technology and 
Society: Interrogating the Nexus, (2013), Routledge. 
52 The HTA 2004 applies primarily in England, Wales and Northern Ireland (except certain sections 
including section 45, which also applies to Scotland, see further below).   
53 Directive 95/46/EC of the European Parliament and of the Council of 24 October 1995 on the 
protection of individuals with regard to the processing of personal data and on the free movement of 
such data, OJ L 281, Nov. 23, 1995. 
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[EU Data Protection] Directive apply. The collection, storage and use of 
tissue samples themselves may be subject to separate sets of rules.54 
 
4.5 More recently, however, in a ruling against the United Kingdom in the context 
of the National forensic DNA Database and indefinite retention of DNA samples of 
persons not convicted of a crime, the European Court of Human Rights ruled that the 
retention of DNA profiles and cellular samples constitute ‘personal data’ under the 
law.55 
 
4.6 There is, therefore, powerful legal support for the view that, as a minimum, the 
entire collection should be treated as ‘data’. This means that we should be concerned 
with personal information held together with the blood samples and information 
derived from those samples as well as the samples themselves. The consequence of 
this is that the entire collection and its uses are subject to data protection law, and we 
discuss the implications of this in the paragraphs that follow. If this position is not 
adopted, and rather a distinction is drawn between the physical samples themselves 
and information derived from the samples or kept with the samples, then the legal 
position in Scotland is complex because, as we discuss in the next section – The 
collection as tissue – there is very little direct legal authority for this position and this 
creates uncertainty about the obligations of those responsible for the resource and 
the rights of people whose tissue are kept as part of the resource.  
 
4.7 There is support in Scotland for the view that the collection should be treated 
as information. The Guide to the required standards of practice in the management of 
records for those who work within or under contract to NHS organisations in Scotland 
(2012) includes newborn screening records and blood spots as health records.56 The 
Health Records Retention Schedule draws a distinction between neonatal screening 
records (presumably for the health interests of the patient) and prescribes a minimum 
retention period of 25 years, while it provides that newborn blood spot screening 
cards should be retained for a minimum of 5 years for quality assurance purposes, 
but that longer retention is recommended in keeping with the Code of Practice of the 
UK Newborn Screening Programme Centre (2005).57 Thus, the Guide links purposes 
and time periods with procedures for justifying on-going retention, although the 
justification for the periods chosen is less obvious. Unfortunately, helpful instructions 
from the last version of the document in 2008 – to the effect that parents should be 
alerted to the possibility of contact from researchers after the minimum period and 
                                            
54 The Article 29 Data Protection Working Party is a group experts established by the European 
Commission to advise member states on the implementation and interpretation of the Data Directive 
which is the basis of the UK’s Data Protection Act 1998. See, Opinion 4/2007 on the concept of 
personal data, 20th June 2007, (01248/07/EN WP 136). On “separate sets of rules” the Working Party 
recommends considering the Council of Europe Recommendation No. Rec (2006) 4 of the Committee 
of Ministers to Member States on research on biological materials of human origin, 15 March 2006. 
55 S and Marper v United Kingdom (2009) 48 EHRR 50, para 68. 
56 The Scottish Government, A guide to the required standards of practice in the management of 
records for those who work within or under contract to NHS organisations in Scotland, [NHS Code of 
Practice: v2.1.] (2012) p.66.  Available at: 
http://www.scotland.gov.uk/Resource/Doc/366562/0124804.pdf   
57 Ibid. 
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that there should be a record of their consent to contact response – have been 
removed.58 Best practice suggests strongly that these be reinstated. 
 
4.8 The consequences of treating the entire collection as information are that it 
becomes subject to the Data Protection Act 1998. This in turn means that the ‘data 
controller’ – being Greater Glasgow & Clyde Health Board and (possibly also) 
National Services Scotland - is responsible for compliance with the provisions of the 
1998 Act. This includes, for example, that the data are held lawfully and fairly; that 
the data are processed only for the original purposes for which they were obtained; 
that the data are not kept longer than necessary to meet those purposes; and that 
they should not be transferred to any other country which does not have similar 
levels of privacy protection. 
 
4.9 A potential complicating factor is that much of the Scottish collection is not 
held in a systematic format; rather many cards are merely stored in boxes arranged 
by year. Normally, for the Data Protection Act to apply personal data must be held in 
a ‘relevant filing system’, that is, in an ordered and accessible way. There are, 
however, two reasons why no attempt should be made to rely on this as a means to 
evade the Data Protection Act. First, the data contained in the collection relate to the 
health of individuals and were collected for health purposes; as such, they constitute 
an ‘accessible record’ which automatically qualifies for legal protection under the 
1998 Act. An additional consideration is the fact that the data are held by a public 
authority meaning that they are ‘Category E’ data59 and also deserving of protection 
(albeit that not all provisions of the 1998 Act apply). In each case, the way in which 
nature of the holding is irrelevant.  
 
The importance – or otherwise – of consent 
 
4.10 Contrary to popular belief, it is not the case that the consent of the individual is 
necessarily required for the processing of his or her data; rather information about 
processing and purposes thereof must be available; moreover, certain exceptions 
apply to the processing of data. These include processing that is necessary for the 
protection of the vital interests of the individual, or for the prevention or detection of 
crime. Importantly, the Data Protection Act does not apply to data relating to 
deceased persons or to data which have been adequately anonymised, i.e., from 
which an individual cannot likely reasonably be identified. In all cases, a lawful basis 
for processing personal data must exist, but consent is only one of a range of 
possible lawful bases. 
 
4.11 Section 33 of the Data Protection Act provides for the so-called ‘research 
exemption’. This can be applied where the processing of personal data is only 
for research purposes, and where the following conditions are met:  
 
 The data are not processed to support measures or decisions relating to 
particular individuals; and  
 The data are not processed in such a way that substantial damage or 
substantial distress is, or is likely to be, caused to any data subject.  
                                            
58 Scottish Government, Records Management: Code of Practice (Scotland) Version 1.0, Annex D 
‘The Management, Retention and Disposal of Personal Health Records’, July 2008, p.88.  
59 ‘Category E’ data are those held by public authorities in non-electronic or un-filed records.  
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4.12 Three important consequences of the application of the research exemption 
are: 
(a) personal data may be kept indefinitely; 
(b) personal data may be processed for purposes other than those for which it 
was originally obtained; and  
(c) data subjects need not be given access provided that they cannot be identified 
from results of the research.   
 
This having been said, the arbitrary retention of records with the abstract hope that 
they might have a future research value is not acceptable. The Information 
Commissioner’s Office has made it clear that: ‘[t]he exemption may only be used…if 
research is actually being carried out or there is a firm intention to use the records for 
that purpose.’60 Data subjects should normally be informed of the prospect of this 
research use of their data. If, however, patients cannot be contacted without 
disproportionate effort then this requirement need not be met. The Information 
Commissioner’s Office advises that this fact should be recorded.61 What constitutes 
‘disproportionate effort’ is a matter of facts and circumstances in each case and the 
advice of the Information Commissioner’s Office should be sought if there is any 
doubt. This does not preclude an effective and sustained public awareness campaign 
about the existence and use of a resource such as the Guthrie collection, as indeed 
was recommended by the Confidentiality and Security Advisory Group for Scotland in 
2002.62  
  
4.13 Apart from the Data Protection Act 1998 and the NHS Guide, a number of 
other laws and policy documents affect record keeping arrangements in NHS 
organisations.63 In particular, legal and professional obligations must be complied 
with (arising from the common law duty of confidentiality and the NHS Scotland 
Confidentiality Code of Practice), including the role of Caldicott Guardians.64 Caldicott 
Guardians play a very important role within the NHS as officers responsible for 
maintaining oversight of legal and ethical propriety of information flows with respect 
to patient confidentiality. A recent review has confirmed their central role in 
information governance, emphasising not only the enduring and vital importance of 
protecting confidentiality, but also now that “The duty to share information can be as 
important as the duty to protect patient confidentiality.”65 Prior professional 
                                            
60 Information Commissioner’s Office, Use and Disclosure of Health Data (2002), chapter 3.  
61 Ibid. 
62 CSAGC, Protecting Patient Confidentiality – Final Report (2002), paras 6.5-6.8, available at: 
http://www.sehd.scot.nhs.uk/publications/ppcr/ppcr.pdf 
63 As the Guide points out, “NHS organisations need robust records management procedures to meet  
the requirements set out under the Data Protection Act 1998, the Freedom of Information (Scotland) 
Act 2002 and the Environmental Information (Scotland) Regulations 2004. In addition they will be 
required to produce and implement a records management plan under the terms of the Public Records 
(Scotland) Act 2011.” (para 17).  
64  http://www.knowledge.scot.nhs.uk/ig.aspx 
65 Dame Fiona Caldicott, Information: To share or not to share? The Information Governance Review, 
March 2013, available at: 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/192572/2900774_InfoG
overnance_accv2.pdf. Note that this report is directed only at England but the comment is made that: 
“…there is much in our report which should prove useful in all the jurisdictions of the United 
Kingdom.”, p.7. 
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undertakings to the public must also be taken into account especially if a shift in 
policy or approach is being contemplated.66 
 
4.14 The relevance of the common law duty of confidence is that this complements 
and in some ways goes beyond the requirements of data protection, most notably 
that the duty of confidence extends after death (albeit not indefinitely).67 Thus, from 
the perspective of management of the collection, although data protection safeguards 
no longer apply to deceased persons, this does not give carte blanche for the use of 
records without considering the requirements of the common law. These include that 
disclosure must be justified on one or more of a limited number of grounds as laid out 
in the Human Rights Act 1998, that is, “...in the interests of national security, public 
safety or the economic well-being of the country, for the prevention of disorder or 
crime, for the protection of health or morals, or for the protection of the rights and 
freedoms of others.”68 We discuss the full implications below.   
 
4.15 Thus, conclusions to note about the collection as information are: 
 
 As a matter of current practice, it would seem that the Guthrie collection is 
treated in Scotland as part of the health record; this has implications for 
retention periods and the legal regimes that apply; 
 As a matter of law, the most relevant provisions are found in the Data 
Protection Act 1998 and the common law duty of confidence, both of which 
must be read in light of the Human Rights Act 1998; 
 Individual rights of privacy over personal information are not absolute nor do 
they require as a strict matter of law the consent of the person; while consent 
is one means to legitimate processing of personal data, other justifications are 
possible but individuals should be able to know the purposes for which their 
data are being processed; 
 Anonymisation of data can greatly minimise the privacy risks and, by 
association, the privacy claims of individuals; indeed appropriate 
anonymisation of data means that the Data Protection Act does not apply;  
 There are merits in treating the sample in itself as personal information for the 
purposes of regulation although – as we discuss in the next section - other 
legal regimes must also be considered.   
 
The collection as tissue 
England 
4.16 In England, blood samples (and, thus, newborn blood spot screening cards) 
are covered by the Human Tissue Act 2004 (HTA 2004), which provides a legislative 
                                            
66 For example, the NHS Scotland Code of Practice on Protecting Patient Confidentiality sets 
expectations against relying on exemptions in the Data Protection Act 1998, s.33 with respect to 
research.  
67 This position has been laid down by the UK Information Commissioner, and upheld by the 
Information Tribunal in Bluck and The Information Commissioner and Epsom & St Helier University 
NHS Trust, 17 September 2007, EA/2006/0090.  
68 The House of Lords has confirmed that the common law of confidentiality must been read in terms 
of the Human Rights Act 1998, see Campbell v Mirror Group Newspapers Ltd. [2004] 2 AC 457, 
[2004] 2 All ER 995. 
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framework for regulating the storage and use of human organs, tissues and cells 
from both living and deceased persons69 for certain “scheduled purposes”.70  Part 1 of 
the Act regulates the removal, storage and use of “relevant material” for the purposes 
outlined in Schedule 1 of the Act, including “research in connection with disorders, or 
the functioning, of the human body”. “Relevant material” is defined as material that 
has come from the human body, which consists of or includes human cells.  Embryos 
outside the human body are excluded, but blood is included.71 
 
4.17 Part 2 of the Act made provision for the establishment of the Human Tissue 
Authority (HTA), which oversees and licenses organisations that store and use 
human tissue for purposes such as research, patient treatment, post-mortem 
examination, teaching, and public exhibitions, and gives approval for organ and bone 
marrow donations from living people.72   
 
4.18 The HTA’s Codes of Practice cover the main aspects of the removal, storage 
and disposal of human organs and tissue. The Codes make clear that material may 
be taken from the living in a variety of circumstances, for example: 
 
 in the course of a diagnostic procedure (e.g., blood sample, biopsy) 
 
 specifically for the purposes of research (e.g., a blood sample taken as part of 
a population screening programme) 
 
4.19 This would seem to put beyond doubt that Guthrie Card collections in England 
are regulated by the HTA 2004 and the Human Tissue Authority. 
 
4.20 The Code on Consent also notes that: “Under the HT Act, consent from the 
living is not needed for storage and use of tissue for: 
 
 clinical audit 
 education or training relating to human health (including training for research 
into disorders, or the functioning, of the human body) 
 performance assessment 
 public health monitoring 
 quality assurance”73 
 
 
 
 
                                            
69 The Human Tissue (Scotland) Act 2006 regulates only the use of human organs, tissue and 
samples from the deceased, which are removed post mortem, and subsequently used for research 
purposes.  It does not regulate the use of human tissue from the living for research. 
70 MRC Regulatory Support Centre, Research and Human Tissue Legislation Series, “Research and 
the Human Tissue Act 2004 –DNA Analysis”, October 2007. Updates available here: 
http://www.mrc.ac.uk/Ourresearch/Ethicsresearchguidance/Useofhumantissue/index.htm 
71 MRC Guide, Clarification p.4. 
72 http://www.hta.gov.uk/aboutus.cfm. A review of fundamental functions of the HTA will be conducted 
in 2013, to report to government in April of that year.  
73 HTA Code of Practice 1: Consent, September 2009, para 114 .  Available at: 
http://www.hta.gov.uk/legislationpoliciesandcodesofpractice/codesofpractice/code1consent.cfm  
30 
4.21 However, consent is normally required to store tissue from the living for: 
 
 obtaining scientific or medical information about a person which may be 
relevant to any other person (now or in the future) 
 public display 
 research into disorders, or the functioning, of the human body and  
 transplantation. 
 
4.22 More specifically on research, the relevant Code of Practice states: “Tissue 
that was taken from the living for diagnosis and subsequently stored in a diagnostic 
archive can be valuable for use in research in connection with the disorders, or the 
functioning of, the human body. Diagnostic tissue can only be released for research 
under the following circumstances: 
 
 When the patient has given consent for use of their tissue in research (the 
preferable scenario); or 
 
 When the tissue will be released to the researcher in a non-identifiable form; 
and 
 
 When the tissue will be used in a project that has approval by a recognised 
research ethics committee (for more information on ethics committees see the 
National Research Ethics Service (NRES): http://www.nres.nhs.uk/ )74 
 
4.23 The HTA 2004 applies only to England, Wales and Northern Ireland EXCEPT 
certain sections, including section 45 – Non-consensual DNA analysis - which also 
applies to Scotland, and this is discussed further below.   
 
Tissue in Scotland 
4.24 If the collection/the physical samples are seen as “tissue” then the legal 
position in Scotland is less clear. As stated above, the Human Tissue Act 2004 does 
not, in the main, apply in Scotland, with the notable exception of section 45 (see 
below). Moreover, the equivalent legislation for Scotland – the Human Tissue 
(Scotland) Act 2006 - does not extend to the Guthrie card collection because it is 
concerned only with material taken from deceased persons or from living persons for 
transplantation purposes. It may therefore be the case that a lacuna in the law exists 
with respect to tissue from the living generally. The common law, that is, judge-made 
law, is of little assistance.75 Almost all of the cases relate to material taken from 
deceased persons76 or are concerned with the criminal law, for example, theft of 
                                            
74 HTA Code of Practice 9: Research, September 2009, para 26, available at: 
http://www.hta.gov.uk/legislationpoliciesandcodesofpractice/codesofpractice/code9research.cfm?faAre
a1=customwidgets.content_view_1&cit_id=757  
75 As McLean et al have commented, “when the retention of tissue from the living [is] considered the 
law [becomes] unclear”, see S McLean et al, „Human tissue legislation: A benefit or a burden?” (2006) 
8(1) Medical Law International 1-21 at 11. 
76 For an in-depth discussion of the position in Scots law see N Whitty „Rights of Personality, Property 
Rights and the Human Body in Scots Law‟ (2005) 9 Edin LR 194 and more recently Stevens v Yorkhill 
NHS Trust and another 2006 SLT 889; 2007 SCLR 606; (2007) 95 BMLR. 
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human material.77 It might be possible to argue that the physical samples are owned 
by those who have created and hold the collection – on an old rule about ownership 
going to those who exercise labour and skill to create something new – but there is 
no direct modern Scottish authority on this point.78 
 
4.25 On questions of property, it is important to be aware of an important decision 
of the Court of Appeal in England in which it was held that men who deposited sperm 
in a fertility clinic and which perished because of negligent storage had a property 
claim against the NHS Trust for resulting emotional harm.79 The influence of this in 
Scotland is open to question because (a) decisions of the English Court of Appeal 
are not binding on Scottish courts, (b) this is an unprecedented decision with unclear 
legal basis, and (c) the decision itself was contingent on the circumstances, that is, 
sperm was deposited with the express expectation that it be returned to the donor at 
some future date. This having been said, two points should be taken from this turn of 
events: (1) it may signal a shift in judicial attitudes towards property-type claims in 
human material, and (2) there might be an analogy with Guthrie spots, viz, one 
purpose for retention is the longer-term health interests of the individual and 
therefore a connection or continuing claim might remain between an individual and 
his or her sample.80     
 
4.26 The only statutory provision of direct relevance to the Guthrie collection in 
Scotland is Section 45 of the Human Tissue Act 2004 (Non-consensual DNA 
Analysis). This in effect creates an offence of ‘DNA theft’. It is concerned with DNA 
analysis only, not with the holding of tissue per se. The basis for this legislation is 
consent, reflecting the cultural and attitudinal shifts which have occurred in the last 
few decades with respect to biomedical collections and practices. That said, while 
consent is now the norm to legitimate actions done with or to biomedical collections 
is in not required in all circumstances. 
 
Lawfulness of continued retention 
4.27 Section 45 of the Human Tissue Act 2004 came into force on 1 September 
2006. Its effect is to create a criminal offence of non-consensual DNA analysis, albeit 
with exceptions, but it does not create a statutory legal basis for the holding of human 
tissue in Scotland. It is, in fact, difficult to find a clear positive legal entitlement for 
continued retention. Arguably, however, in such cases an old maxim of the law 
applies: nulla poena sine lege (no penalty without law). Put another way, ‘that which 
is not illegal is legal’. It does not follow, however, that the Guthrie collection can be 
used freely because wider ethical considerations must also be borne in mind, as 
should the possibility of the criminal offence of non-consensual DNA analysis.81 
Moreover, there is an important distinction to be drawn between hard and soft law. 
                                            
77 R v Rothery [1976] RTR 550, (1976) 63 Cr App R 231 and R v Welsh [1974] RTR 478. 
78 For English authority on this point see R v Kelly [1998] 3 All ER 741. 
79 Yearworth v North Bristol NHS Trust [2009] EWCA Civ 37; [2009] 2 All ER 986; [2009] 3 WLR 118; 
(2009) 107 BMLR 47. For commentary on this ruling and its likely implications, see S.H.E. Harmon 
and G.T. Laurie, 'Yearworth v. North Bristol NHS Trust: Property, principles, precedents and 
paradigms' (2010) 69 Cambridge Law Journal 476-93. 
80 For discussion of possible ramifications and the on-going uncertain legal nature of any consent that 
is provided, see G. Laurie and E. Postan, 'Rhetoric or Reality: What is the Legal Status of the Consent 
Form in Health-related Research?' (2012) Medical Law Review 44pp, doi: 10.1093/medlaw/fws031 
81 See Human Tissue Authority, Code of Practice 1: Consent, 2009. paras 152-156.   
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Hard law, such as Acts of Parliament or case law, is a more formal expression of the 
legal system and political will. Soft law, in the form of guidance or governance 
arrangements, can be equally and sometime more effective. It is certainly the case 
that NHS Scotland has a robust system of research governance procedures. NHS 
Scotland has brought the collection within the remit of these procedures to help to 
ensure appropriate oversight. We assess these measures in chapter 7.   
Lawfulness of use – section of the 45 HTA 2004 (Non-consensual DNA 
analysis) 
4.28 Section 45 of the Human Tissue Act 2004 provides that a person commits a 
criminal offence82 if he has any bodily material83 intending that any human DNA in the 
material be analysed and (a) there is no consent to such analysis, or (b) the results of 
the analysis are not for an ‘excepted purpose’ as prescribed by the law. These 
purposes include the prevention or detection of crime, conduct of a prosecution and 
purposes of national security.   
4.29 This provision of the law has two important qualifications of relevance to the 
Guthrie Collection. First, the legal position regarding ‘existing holdings’, i.e., material 
held prior to the section coming into force (1 September 2006), and, second, the 
research exemption which relates to material taken from living persons after that 
date. 
4.30 As regards existing holdings, DNA analysis is lawful for a finite list of purposes 
even if the samples are identifiable and even if no consent has been obtained. This 
list includes clinical audit, research in connection with disorders, or the functioning, of 
the human body, and obtaining scientific or medical information about a living or 
deceased person which may be relevant to any other person (including a future 
person). 
 
4.31 As regards the research exemption, the results of DNA analysis may be used 
for research in connection with disorders, or the functioning, of the human body 
without consent, providing that: 
 
 the bodily material concerned is from a living person; and 
 the research is ethically approved in accordance with regulations made 
by the Secretary of State; and 
 the researcher is not in possession, and not likely to come into 
possession of information that identifies the person from whom it has 
come. 
 
                                            
82 Pursuant to section 45(3), a person found guilty of an offence under this section is liable on 
summary conviction to a fine, or on indictment to imprisonment for a term not exceeding 3 years, or a 
fine, or both.  
83 “Bodily material” is defined in section 45(5) as “material which has come from the human body 
[living or deceased] and consists of or includes human cells”.  This definition covers human blood, as it 
‘consists of or includes human cells’; it does not, however, cover extracted DNA or RNA where no 
whole cells remain. This definition, thus, covers newborn blood spot screening cards. 
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4.32 In other words, scientifically sound, ethically approved and adequately 
anonymised research for human health purposes is lawful under the 2004 Act.  
The Human Tissue Authority provides advice on the application of this section of the 
2004 Act to Scotland.  
4.33 Conclusions to note about the collection as tissue: 
 
 There is no clear legal basis in Scotland to regulate the collection as tissue, 
with the exception of section 45 of the Human Tissue Act 2004; 
 This section merely concerns DNA analysis and creates an offence for which 
exemptions apply;  
 The existence of the collection as an existing holding does not require specific 
consent but careful attention is required to questions of access and use; 
 As with data protection, anonymisation of the collection for use can elide a 
number of legal concerns (see further below under Consent, Chapter 5) 
 Appropriate ethical oversight of the collection is required in order to conform 
with the provisions of section 45 of the 2004 Act.  
 
The human rights dimension 
4.34 All laws and practices must respect the human rights of UK citizens. Thus, in 
order to obtain the complete legal picture with respect to the Guthrie collection it is 
essential to consider the human rights dimensions. 
 
4.35 The ruling of the European Court of Human Rights in Marper, see above, has 
cast some light on these dimensions with respect to DNA collections (albeit in a 
forensic setting). It was held in that case that the blanket policy of the UK to retain 
DNA profiles and samples indefinitely when taken from persons without their consent 
and who had not been convicted of a crime was an unjustified breach of their human 
rights. Indeed, it held that the mere retention of DNA, even without use, was an 
interference with the right to respect for private life because of the possible 
implications that future uses could have for individuals. This might raise obvious 
questions for elements of a Guthrie collection for which current explicit consent is not 
operating, i.e., the historical collection. But it does not follow that long-term retentions 
must cease; it might mean, however, that the procedures for governance should be 
strengthened. 
 
4.36 Human rights law seeks balance and even interference with individual rights 
can be lawful so long as it is justified. Justification is a three-prong test: 
 
 I. In accordance with the law 
 
 This means that measures must have a basis in domestic law; the law must be 
adequately accessible and foreseeable and with sufficient precision for 
individuals to know how it operates; and there must be sufficient protection 
from arbitrary decisions and clarity of the scope of discretion. Whether these 
criteria are met depends on all circumstances in a given context. As has been 
demonstrated, there is an absence of any specific hard law basis for taking 
and retaining blood spots in Scotland. This places all the more emphasis on 
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the soft law conditions attached to, and arrangements for, the storage and use 
of the collection. This issue was of particular concern for the European Court 
of Human Rights in Marper and suggests that robust, transparent policies and 
procedures are essential. We return to this below.   
 
 II. Legitimate aim 
 
 This means that the measure must further one of the aims mentioned above. 
The health of individuals and others, social welfare and the prevention of 
disorder or crime are all legitimate aims; but these are further qualified by the 
final criterion. 
 
 III. Necessary in a democratic society 
 
 This means that the measure must show that it addresses a “pressing social 
need”, that its operation is proportionate and that the reasons advanced for its 
existence are “relevant and sufficient”. It is the obligation of authorities to 
demonstrate that they meet these criteria. 
 
4.37 Conclusions to note about the human rights dimension. 
 
 All laws and practices must be compliant with human rights 
 To test human rights compliance, we must ask if (1) a measure is in 
accordance with the law, (2) pursues a legitimate aim, and (3) is 
necessary is a democratic society. If this test can be met then a 
measure is lawful even if it engages individual human rights.  
 In the context of DNA collections, the Marper case held that it was the 
blanket and indiscriminate nature of the policy which was unjustified. 
 The fact that consent provisions have been introduced to the regulation 
of the Guthrie collection indicates that no such charge could be levelled 
in the current context. But the question of the historical collection 
remains as this affects persons is categories 1, 2 and 4 in Chapter 3.  
 
The options for the future of the collection include:  
 
(a) complete destruction,  
 
(b) attempts to obtain informed consent for people whose cards are held as part of 
the collection,   
 
(c) a clear, well-publicised, accessible and efficient opt-out system.  
 
In deciding between options the guiding parameters are whether the ultimate 
decision embodies a proportionate and justifiable policy.    
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POINTS TO CONSIDER AND RECOMMENDATIONS FROM CHAPTER 4 
 
 The Guthrie collection should be treated as both personal information 
and human tissue for the purposes of robust governance.  
 
 The existing collection is not unlawful but careful attention must be paid 
to matter of governance, especially those concerning future use and 
access. 
 
 Consent to use is not an absolute requirement but should not be 
departed from lightly. 
 
 Anonymisation can remove some legal obligations but not all 
obligations; moreover, it is not a complete answer to the challenges 
thrown up by the collection. 
 
 Human rights are a consideration across all areas of law. All 
mechanisms, policies and procedures should be tested for human rights 
compliance.  
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CHAPTER 5: CONSENT AND ANONYMISATION 
 
Key questions addressed by this chapter are: 
 
 Should specific consent be sought from all persons whose samples and 
information are held as part of the Guthrie collection?  
 
 What are the arguments for and against this approach?  
 
 What does the law and good practice require?  
 
 What are the alternatives? 
 
 Can the collection be kept and used if the cards are anonymised?  
 
 Is it possible or practical to do so?  
 
 What are the pros and cons of anonymisation?  
 
Key messages from this chapter are: 
 
 The law does not require that specific consent be sought from all 
persons whose samples or data are held in the Guthrie collection; it is 
for consideration none the less, whether such consent should be sought 
as a matter of good practice. 
 
 If specific consent is not sought, there must be a robust system of opt-
out to respect persons whose samples/data are contained in the 
collection. 
 
 Because people consent to inclusion in the collection on the basis of 
broad consent, attention should be given to how they will be kept up-to-
date with uses of the resource as and when these occur. 
 
 It is for consideration whether a system of ‘consent for consent’ should 
be considered to facilitate access to the Guthrie collection for research 
purposes; caution should be exercised, however, about adopting a 
presumed consent approach. 
 
 Specific consent should be sought from individuals if access is 
contemplated for non-standard purposes, e.g. non-health-related 
research. 
 
 It is for consideration whether mature minors should be allowed to opt-
out of the collection.
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 Transparent procedures should be developed for circumstances where 
access will be given without consent but subject to suitable 
authorisation. 
 
 Transparent procedures should be developed to decide whether and 
how access will be granted if neither consent nor anonymisation is 
possible. 
 
 Consideration should be given to scrutiny mechanisms authorising 
access even when anonymisation is contemplated. 
 
 A policy should be developed on whether and how feedback of 
individual results will be given. 
 
 A decision should be taken on Open Access to the resource or results 
from the resource. 
 
 A Privacy Impact Assessment should be carried out on the Guthrie 
collection. 
 
DISCUSSION 
Consent: the issues 
5.1 This section discusses the function of consent, ethically and legally, and raises 
some issues for the collection. The next section addresses the most viable 
alternative, namely, anonymisation. 
 
5.2 The purposes for which the Guthrie collection is maintained, the role of 
consent and the requirements of the relevant legal regimes are inextricably linked. 
The introduction of an informed consent system addresses many of the ethical, legal 
and social issues surrounding the collection but it is not a panacea nor should it be 
considered as such. Even for those who have given consent there are questions 
about the degree to which this was sufficiently informed (for example in relation to 
current procedures for police requests for access, and as yet untested applications 
by commercial interests such as pharmaceutical companies – see Chapter 6). These 
matters could clearly be addressed for the future. More difficult issues relate to the 
elements of the collection relating to persons for whom specific consent was not 
given, either those who are now adults or those who are still children. If consent were 
thought to be the ‘best practice’ option this would raise a plethora of social and 
economic issues and would bring with its own set of ethical concerns.  
 
The function of consent 
5.3 Consent is merely a device to show respect to persons, it is not an ethical 
value in its own right. Moreover, there are many different models of consent which 
are in use.  
 
5.4 The lingua franca of modern medicine is informed consent, and this works 
best in the context of treatment or clinical trials when individuals can be fully informed 
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before committing to a course of action about what will happen, the consequences, 
risks and alternatives. This model does not work for collections like the Guthrie 
collection. Equally, while presumed consent can be inferred from individuals’ actions, 
this only has a very narrow sphere of legitimate operation – for example when a 
patient offers his or her arm for blood to be taken. In particular, it is not at all clear 
that consent can be inferred from non-action. This raises questions about the 
information material given to parents. The section on research states: “If you do not 
want the stored blood spot card to be used for research, please ask the midwife to 
write ‘no research’ in the comments box on the blood spot card.”84 Can it be inferred 
from a blank box that consent has been given? Matters would be clearer if a 
positive assent to research was recorded.    
 
5.5 The approach with the Guthrie collection is one of broad consent whereby 
individuals are presented with a broad proposition and asked to agree to participate. 
Clearly all future uses, research or otherwise, cannot be explained before consent is 
given. None the less, arguably the ethical (and legal) obligation is to keep people 
informed of uses as and when they occur. If this does not happen people might lose 
trust in the system if they discover uses of which they would not have approved. The 
experience of Texas, para 2.18 above, is a clear example of this.  
 
5.6 Existing projects that rely on broad consent, such as UK Biobank,85 always 
provide an opt-out or withdrawal mechanism. Keeping people informed about the 
uses of a collection, e.g. via regular updates on a website, can help to ensure 
transparency and give meaning to a right to withdraw. Moreover, human rights would 
suggest that the onus is on those responsible for the collection to demonstrate and 
justify the continued need for, and value of, its retention. It will be recalled from para 
4.12 that arbitrary retention of records with the abstract hope that they might have a 
future research value is not acceptable. A clear commitment to a research purpose 
and demonstrate utility is required.  
 
5.7 The ethical imperative in all dealings with patients is to respect them. There 
may be many ways to respect individuals, their rights and their interests which do not 
require consent. It is essential, therefore, to identify which interests or rights are at 
stake for people with respect to the Guthrie collection. Two stand out as having 
paramount importance: privacy and autonomy (freedom of choice).  
 
5.8 Assuming the lawfulness of the existing collection in terms of continued 
storage, the next question is whether specific consent for on-going use should be 
sought. We make no comment here about the resource implications of such a policy 
or the procedures that this would involve. Consent could operate in a variety of ways 
with respect to future use of the resource. We can consider the following questions.  
 
5.9 Should “consent for consent” be sought in the context of research use? 
There is on-going contemporary discussion about the need for, and utility of, seeking 
“consent for consent” with respect to use of health data for research purposes. It is 
argued in some quarters that individuals should be actively approached, or at least 
informed, about the prospect of their medical data being used for research and given 
                                            
84 NHS Scotland, Your Guide to Newborn Screening Tests, (2012), p.20. 
85 See the details of the UK Biobank Ethics and Governance Framework here: 
http://www.ukbiobank.ac.uk/wp-content/uploads/2011/05/EGF20082.pdf 
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the opportunity to consent to being contacted for specific consent at some future 
date, or alternatively, to refuse any such approach. There are serious practical and 
economic consequences of adopting this approach, but its application to the Guthrie 
collection raises no novel issues not already being discussed in the wider community.   
 
5.10 Should specific consent be sought only for specific purposes, e.g., a 
specific research project? The logistics of this would be considerable if it were to 
occur for every research use. It might, however, be used for research uses which 
reasonable persons would not consider to be within the original purposes of a 
collection such as Guthrie cards. An example of such a use might be non-health-
related research.86  
 
5.11 What is the role of opt-out/on-going obligations of keeping the public 
informed about issues of use and access? We suggest that given the nature of 
consent that has been obtained since 2003 (broad consent) and the absence of 
consent before 2003, there is an imperative to keep people informed about the 
collection and the uses to which it is put and, ideally, to involve them in processes for 
deciding future policy. This does not necessarily mean that every individual should be 
contacted individually.87 Furthermore, given the interest in freedom of choice, this 
supports a robust opt-out mechanism.  
 
5.12 What is the position with respect to the mature minor/minor assent? The 
law recognises that children can be sufficiently mature to take health-related 
decisions about their own care before they are 16.88 In keeping with the spirit of this 
law, there is a strong case for arguing that mature children should be able to opt-out 
of the collection should they choose to do so. A counter argument to this is that their 
continued inclusion in the collection might be a necessary part of their own medical 
record. In the event of any dispute about whether to retain or destroy a mature 
minor’s sample and data, the guiding legal principle would be best interests to be 
resolved by a court in the ultimate resort.  
 
5.13 Is consent required at all if, all things considered, risks are minimal or 
non-existent? In the absence of any expression of choice by a person or their 
representative to opt-out, the remaining serious risk is to privacy. We suggest, in 
keeping with other ethical models of biomedical governance, that if privacy risks can 
be shown to be minimal and ethical approval for access has been granted by a 
relevant and authorised body or person (such as a Caldicott Guardian), then access 
can be granted without prior consent. The mechanics of this are best dealt with under 
Governance, below. The most likely privacy protection mechanism in such cases is 
anonymisation, and it is to a consideration of that issue that we now turn.  
                                            
86 M.T. Lysaught et al, ‘A Pilot Test of DNA-based analysis using anonymized newborn screening 
cards in Iowa’, in R.F. Weir ed., Stored Tissue Samples: Ethical, Legal and Public Policy Implications 
(University of Iowa Press, 1998). 
87 This is accepted by bodies such as Genewatch. See: ‘Keeping blood spots from newborn babies’, 
January 2006, available at: http://www.genewatch.org/pub-507666, p. 3, citing J. Kaye, (2004) 
Abandoning informed consent: the case of genetic research in population collections; S. Weldon, 
(2004) ‘Public consent’ or ‘scientific citizenship’? What counts as public participation in population-
based DNA collections? Both in: R. Tutton and O. Corrigan (eds) Genetic databases: socio-ethical 
issues in the collection and use of DNA. London, Routledge. 
88 See the Age of Legal Capacity (Scotland) Act 1991, s.2(4) although it is unclear if this extends to 
refusals. 
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Anonymisation: the issues 
5.14 It should be clear from the previous section that while consent has a role to 
play in legitimating actions which might otherwise be illegal, it is not the only means 
to do so. Information can be processed without consent to promote recognised public 
interests, such as the prevention or detection of crime, and/or because other safety 
mechanisms can be used to protect individuals’ interests and which do not require 
specific consent. Anonymisation is the paradigm example of this and is frequently 
used in research ethics to protect participants’ privacy. Both data protection laws and 
human tissue legislation envisage a role for anonymisation.89 Thus, anonymisation 
can serve in protecting privacy interests while seeking to maximise the use of the 
resource.90 As with consent, however, anonymisation is not a solution to all 
challenges thrown up by all uses of the resource. Specific issues to consider include: 
 
 I: Anonymisation is not always possible from the privacy perspective 
 There is considerable debate about what ‘anonymisation’ actually means.91 
For example, is it absolute anonymity that is required such that no person can 
ever be identified from information/material?, or is it relative anonymity such 
that it is not reasonably likely that the person will be identified? It has been 
increasingly demonstrated that that the former is not possible in the context of 
genetic material and other personal data,92 while the latter is probably all that 
is required by law.93  More recent contributions to the Scottish Guthrie 
collection are reversibly anonymised, but this is not true for the majority of the 
collection where personal information and the sample are held together on the 
same card. This has implications for what people are told about the risk 
to their privacy.  
 
 Expectations couched in terms of guarantees of privacy protection should be 
avoided; expectations must be realistic and the reality is the any use of 
personal data, even anonymised data, increases privacy risks. To 
appropriately assess the range of privacy risks, we recommend a regular 
Privacy Impact Assessment of the Guthrie collection in Scotland. Details 
are available from the Information Commissioner’s Office94 and the Information 
Services Division in NHS Scotland has already conducted such exercises.  
 
                                            
89  The effect of anonymisation for data protection and human tissue regulation purposes is that those 
processing anonymised data/tissues do not have to comply with the provisions of the legislation, for 
example, researchers receiving suitably anonymised samples/information. This, however, clearly does 
not absolve the custodians of the collection from complying with the relevant laws since they hold both 
the collection and personal data from which specific individuals can be identified.  
90 See further, W. Lowrance, Privacy, Confidentiality and Health Research (2012). 
91 W. Lowrance and F.S. Collins, ‘Identifiability in Genomic Research’ (2007) 317:5838 Science 600-
602.   
92 For discussion, see J.K. Mason and G.T. Laurie, Law and Medical Ethics, 9th ed, 2013, chapter 6.  
93 This point of law was not ultimately determined by the House of Lords in Common Service Agency v 
Scottish Information Commissioner [2008] UKHL 47, 2008 SLT 901. For comment see G. Laurie and 
R. Gertz, ‘The worst of all worlds? Common Services Agency v Scottish Information Commissioner’ 
(2009) 13 Edin LR 330. 
94 http://www.ico.org.uk/for_organisations/data_protection/topic_guides/privacy_impact_assessment  
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 II. Anonymisation is not always possible from the research perspective 
 Some kinds of research are not possible using anonymised data, i.e., 
identifiable or potentially identifiable data are required in order for the research 
to be carried out.95 While the possibility of seeking specific consent remains, in 
many cases it is not reasonable or practicable to pursue this route. In other 
countries, legislation has been introduced which allows a designation body to 
authorise uses of information without consent when use would otherwise be 
unlawful, e.g., a breach of confidence. The Ethics and Confidentiality 
Committee performs this role for England & Wales under the auspices of the 
Health Research Authority96 and operates on a statutory footing.97 A similar, 
although not identical function is performed in Scotland by the Privacy 
Advisory Committee (PAC) but this body does not have a statutory basis. PAC 
exists to advise the institutions that set it up, being the NHS National Services 
Scotland (NSS) and National Records of Scotland (NRS). It considers 
applications for linkages of identifiable data from any datasets held under the 
auspices of these bodies. The Guthrie collection is not such a collection as 
such – it is held under the auspices of the Greater Glasgow and Clyde Health 
Board. PAC would only have a role with respect to any requests to link data 
from the collection to other datasets held by NSS or NRS. Therefore, PAC has 
no direct remit over the Guthrie collection per se. This means that requests 
merely to access the Guthrie collection without other linkage to other datasets 
must be governed by other means. The operation of the Caldicott Guardians 
system is integral to these mechanisms in the United Kingdom. As stated 
previously, these Guardians are responsible for protecting patient 
confidentiality and exist in each of the Scottish Health Boards. Thus, the 
Greater Glasgow and Clyde Guardian will have a responsibility for the Guthrie 
collection and can play a vital role in decisions about access and use. The 
point to note here is that the traditional approach of „consent or 
anonymise‟ is not always possible for all kinds of research. 
Authorisation is another valid route. We return to consider this in the 
section on Governance, below.    
 
 III: Anonymisation can lead to potential harm to other individual interests  
 What are the obligations that exist between researchers and research 
participants and how are these affected by anonymisation? For example, is 
there a duty to feedback results if health-relevant information is generated as a 
result of research? How would this be possible if anonymity is to be 
preserved? This is a difficult issue in the research community on which opinion 
is currently divided.98 It is important to compare and contrast, however, two 
situations in the context of the Guthrie collection: (i) monitoring infection rates 
in women/children, which is the confirmation of a specific diagnosis and 
                                            
95 D.R. Karp et al. „Ethical and practical issues associated with aggregating databases‟ (2008) 5 PLoS 
Med. e190. 
96 http://www.hra.nhs.uk/ 
97 National Health Service Act 2006, ss251-252.  
98 See: S.M. Wolf, „The challenge of incidental findings‟ (2008) 36 J. Law Med. Ethics, and the other 
articles in this symposium edition. Cf, F.A. Miller, R. Christensen, M. Giacomini and J.S. Robert, „Duty 
to disclose what? Querying the putative obligation to return research results to participants‟ (2008) 
34(3) Journal of Medical Ethics 201-13. 
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therefore of direct significance to someone's health,99 and (ii) the creation of 
generalisable knowledge on a population level which is only statistically 
significant at that level, that is, the chances of saying something about an 
individual's health status is very slim. Either way, what, if any, feedback 
policies are in place with respect to the uses of the Guthrie spot 
collection? Has this issue been considered? How would it be managed 
and what are the implications of any given policy? We are not aware of 
any consideration of these issues and therefore recommend that 
attention be given to the subject.  
 
 IV: Anonymisation and the specifics of genetic information 
 It is trite to confirm that every individual's genetic data are unique to them 
(absent the case of homozygous twins); in terms of anonymisation and 
identifiability, therefore, it suggests that genetic data/samples always point to a 
particular individual (or pair of individuals). This reality can impact significantly 
on the deliberate balance between access policies and privacy protection.100 A 
recent experience illustrates the point well. The U.S. National Institutes of 
Health and the Wellcome Trust hurriedly revised their policy of open access to 
genome-wide association materials after it was shown statistically how 
individuals could be identified from aggregated data available on the public 
site.101 There is serious doubt about attempts to make genetic or genomic 
data available on an open access basis, even if it is thought that 
anonymity has been achieved; once again, it has implications for access 
policies as we discuss below. 
         
 V. Anonymisation and authorisation 
 Given the comments above, and in keeping with conclusions about consent, 
we suggest that consideration should be given to whether appropriate 
authorisation of access should be given even if a proposal for access is for 
anonymised use of samples/data. This is not only to address concerns about 
individual’s privacy but also because there might be wider, social impacts of 
(research) access depending on the purposes for which access is sought. This 
is particularly the case for the Guthrie collection due to the coverage of the 
collection and the potential for the collection to be misrepresented as a de 
facto “DNA database” for the Scottish population born since 1965.102   
                                            
99 K.M. Boyd, Institute of Medical Ethics: working party report: ‘HIV infection: the ethics of anonymised 
testing and of testing pregnant women’ (1990) 16 J. Med. Ethics 173-178. Cf – A.J. Pinching, ‘The 
ethics of anonymised HIV testing of pregnant women: a reappraisal’ (2000) 26 J. Med. Ethics 22-24. 
100 M.J. Taylor, Genetic Data and the Law: Critical Perspectives on Privacy Protection (2012). 
101 N. Homer et al ‘Resolving individuals contributing trace amounts of DNA to highly complex mixtures 
using high-density SNP genotyping microarrays’ (2008) 4 PLoS Genet. e1000167. 
102 See: M.T. Lysaught et al, ‘A pilot test of DNA-based analysis’, p. 23, where the authors comment: 
“…the trend toward seeing newborn screening labs as DNA databanks which can provide samples for 
secondary purposes has fundamentally altered the nature or status of the blood-spot filter card.  
Previously, one could have argued that newborn screening was simply one of a series of diagnostic 
assays performed under the umbrella of general parental consent to actions promoting neonatal 
health.  But now the blood-spot filter card has become a commodity, an item with “value”, to be used 
for purposes unrelated to the health of the individual newborn.  In this new context, it will be 
increasingly difficult to justify conducting newborn screening in the absence of informed consent.” 
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POINTS TO CONSIDER AND RECOMMENDATIONS FROM CHAPTER 5:  
 
 The law does not require that specific consent be sought from all 
persons whose samples or data are held in the Guthrie collection; it is 
for consideration none the less, whether such consent should be sought 
as a matter of good practice. 
 
 If specific consent is not sought, there must be a robust system of opt-
out to respect persons whose samples/data are contained in the 
collection. Robust in this context means that clear and detailed 
information be publicly available both about the existence of the 
collection and any uses to which it is put. Citizens must be able to 
access procedures for opt-out easily and have their wishes respected in 
a timely fashion. 
 Because people consent to inclusion in the collection on the basis of 
broad consent, attention should be given to how they will be keep up-to-
date with uses of the resource as and when these occur. 
 
 It is for consideration whether a system of ‘consent for consent’ should 
be considered to facilitate access to the Guthrie collection for research 
purposes; caution should be exercised, however, about adopting a 
presumed consent approach. The parent information and consent leaflet 
should be revised to make consent for research an explicit option.  
 
 Specific consent should be sought from individuals if access is 
contemplated for non-standard purposes, e.g. non-health-related 
research. 
 
 It is for consideration whether mature minors should be allowed to opt-
out of the collection. 
 
 Transparent procedures should explain in accessible format the 
circumstances in which access will be given without consent but subject 
to suitable authorisation. 
 
 Transparent procedures should explain whether and how access will be 
granted if neither consent nor anonymisation is possible. 
 
 A policy should be developed on whether and how feedback of 
individual results will be given. 
 
 A decision should be taken on Open Access to the resource or results 
from the resource. 
 
 A regular Privacy Impact Assessment should be carried out on the 
collection.  
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CHAPTER 6: STORAGE AND ACCESS 
 
Key questions addressed by this chapter are: 
 
 What kinds of uses should the collection be put to and which are lawful?  
 
 Should access be allowed for health research?  
 
 What other non-health research access is currently possible, and who is 
likely to request future access? 
 
Key messages from this chapter are: 
 
 The need for a clear, robust and transparent access policy for the 
Guthrie collection in Scotland is non-negotiable in terms of ethical and 
legal requirements; this must cover all current and foreseeable future 
uses of the resource; 
 
 This policy should include guidance for decision-makers on relevant 
factors to take into account. This might include:   
 
o scientific or public value of the project;  
o ethical concerns both for individuals and society;  
o the pressing social need for the access;  
o whether consent can and should be sought for access;  
o any consequences of access for the resource; e.g. use of 
depletable samples, and  
o ways to minimise any adverse impact of the access. 
 
 There should be some mechanism for prioritising research requests; 
 
 A written protocol for the release of samples and information to the 
police be developed and made publicly available; 
 
 Personnel within the NHS should act as gatekeepers with respect to 
access requests, and most notably and ideally Caldicott Guardians 
should be involved in all decisions;  
 
 Given the existence of an opt-out system, consideration should be given 
to the mechanism for adequately informing people about withdrawing 
consent if the person no longer wants the blood spot card to be used for 
research or other purposes; 
 
 Consideration should be given to the specific role of any Access 
Committee and/or oversight body in this regard (see further Chapter 7);  
 
 Those responsible for the collection must clearly define the purposes of 
the collection and link these to justifiable periods of retention. 
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 Consideration needs to be given to the appropriateness of the physical 
environment in which the collection is held and the way in which it is 
archived. 
 
DISCUSSION  
 
6.1 There is a growing awareness that Guthrie card collections are potentially 
valuable sources of DNA for genetics research, and requests for access to the 
collections are increasing. Access to Guthrie cards for secondary uses raises 
numerous ethical issues, including privacy, confidentiality and genetic discrimination; 
these are compounded by the potential for requests for commercial access and 
access by non-health motivated parties, such as employers or insurers. 
 
6.2 Storage and access are, of course, connected to issues of consent and 
anonymisation, which were discussed in the previous chapter. This chapter will focus 
on some of the ethical and practical considerations with regard to storage and 
access, and will make offer a number of points for consideration to improve current 
procedures. 
 
A range of possible uses  
6.3 As noted in Chapter 3 Figure 1, Guthrie cards are currently used for a number 
of purposes and might be used for other purposes in the future.  
 
6.4 There are both practical and ethical issues to consider in terms of storage of, 
and access to, the Guthrie collection.  One of the central concerns is that the 
indefinite or permanent retention103 of the blood spots creates in effect, what could be 
viewed as, a de facto DNA database. This raises questions about how decisions are 
made regarding research access, how people’s rights and privacy are protected, and 
how the involvement of commercial interests is taken into account in access 
decisions. Beyond this, concern lies with public perception of currently tightly 
controlled police access. (see Chapter 9 below). 
 
Storage periods 
6.5 The question of the legitimacy of retention periods for samples in the collection 
is important. In particular, it is noted that the current initial retention period of 1 year 
in Scotland – as detailed in the parental information leaflet104 - is at odds with the UK 
NSPC guidance which suggests 5-years retention for quality assurance purposes. 
Data protection, in turn, requires that data are kept only so long as necessary for the 
original purposes for which they were gathered. This means that those responsible 
for the collection must clearly define the purposes of the collection and link 
these to justifiable periods of retention. What, for example, justifies one year and 
not a longer or shorter period of time? Clearly, different purposes can justify different 
retention periods, but as noted above, as the purposes move further away from 
individual health interests, the justification required is stronger.    
                                            
103 The 2005 Consultation on the ‘Storage and use of newborn babies blood spot cards’, raised the 
issue of permanent retention of the cards.  
104 NHS Scotland, Your Guide to Newborn Screening Tests, (2012), p20. 
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Practical considerations 
6.6 If the collection is to be retained indefinitely and is to be available for health-
related research or indeed any other purposes, then it must be fit-for-purpose(s). 
Consideration thus needs to be given to the appropriateness of the actual 
physical environment in which the collection is held and the way in which it is 
archived. In this regard the importance of the NHS Scotland Guide on Records 
Management contains guidance on archiving collections. Also, the designation of the 
Guthrie collection as a national research collection means that it comes under NHS 
Research Scotland Guiding Principles for Governance of NHSScotland Tissue for 
Research. Such collections have NHS Research Ethics Committee approval to 
operate as a generic research tissue bank, and this means giving approval for 
research studies using human tissue. It should also be kept in mind that the 
European Court of Human Rights has indicated that the storage and use of cellular 
material interferes with an individual’s right to respect for private life and that suitable 
mechanisms for storage and use must be in place (see Chapter 4 above). 
  
Access 
6.7 Requests for access to the Scottish Guthrie collection have been handled in 
the past on an ad hoc basis. However, with increased requests for access for a range 
of purposes, the potential for requests for commercial use of the collection, and 
increased attention to biomedical governance, it is imperative that robust 
mechanisms, policies and procedures are in place that are in accordance with 
the law105 and in line with national guidance. This is important both for the 
protection of individuals whose samples/information are held as part of the collection, 
but also to assist the NHS Greater Glasgow & Clyde Biorepository staff in making 
decisions about requests for access to the collection. As we discuss in the next 
chapter, these decisions might involve the appropriate Caldicott Guardian and/or a 
suitable authorising body. The status of the Guthrie collection as a national research 
collection now means that any researcher who wants access must follow the 
nationally-agreed Access Policy. This includes provisions on ensuring that data are 
anonymised, that some of the bloodspot is retained for patient and family health 
screening, and that researchers share the data collected so that it can be used in 
future studies. In other words, there is a commitment to benefit sharing.  
 
Considerations for access:  
6.8 Research using Guthrie Cards for secondary purposes should not only be 
scientifically sound, but should also produce some “useful information” or clear 
health-related “benefit” even if this is to a broad (and/or future) category of persons.106   
 
6.9 In all likelihood, most interest in access to the Guthrie collection will be for 
genetic research as it represents a potentially very valuable resource. The use of the 
collection for genetic research is contested, however, because the actual benefits of 
any research using such a resource remain unproven and because of the spectre of 
                                            
105 See Chapter 4 above on human rights requirements.  
106 Lysaught et al, ‘A pilot test of DNA-based analysis’, p.25. 
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discrimination for groups of persons on genetic grounds.107 There are also fears 
about the collection being seen as de facto National ‘DNA Database’.108 All of these 
issues are potentially exacerbated by the prospect of requests for commercial 
interests, as we discuss in the next section.  
 
6.10 Considerations are different depending on whether access is sought to 
information or samples. While information is an inexhaustible resource, the same is 
clearly not true for physical samples. Issues of prioritisation must be addressed. 
Moreover, while information might readily be subject to anonymisation processes, the 
same is not possible for a DNA sample which points to a single individual. In other 
words, privacy risks vary depending on the types of access sought. Indeed, even if 
consent for research is thought to be necessary, for example because the sample 
card will be accessed or the research is non-health related, it is vital that approaches 
to individuals and their families are handled in a sensitive and ethically appropriate 
manner. All of these considerations and more need to be considered in any 
access policy.     
 
I: Commercial interests 
6.11 The Newborn Blood Spot Screening Code of Practice for the Retention and 
Storage of Residual Spots, states that: 
 
Newborn screening laboratories may not sell, or grant exclusive access 
to, residual newborn blood spots to commercial organisations.  Some 
commercial partnerships may be required to develop screening 
methods that may benefit the screening service and public health more 
generally.  These arrangements will be subject to scrutiny by the 
Programme Centre Board and will be documented in the Programme 
Centre’s annual report. 
 
6.12 The Code does not, however, address commercial access for research, and 
leaves it to the Board of each Centre to scrutinise arrangements for commercial 
partnerships individually. The proposed access provisions for the Scottish Guthrie 
collection envisage an Access Committee or Governance Board that would address 
such issues. The NHS Research Scotland guidelines make it clear that: “tissue 
should be made available to all legitimate researchers including commercial entities. 
Access should be as broad as possible.”  
 
6.13 Lysaught et al have commented that commercial use “is an area that has 
received the least attention”.109  They note that commercial access raises issues of 
ownership and profit-sharing, and suggest that release for commercial purposes 
could only be justified “in the context of an investigation explicitly designed to benefit 
public health, particularly the goals of newborn screening (i.e., diagnosis of 
conditions for which treatment will make a difference)”.110  This in turn, however, 
                                            
107 See: B. Almond, ‘Genetic profiling of newborns: ethical and social issues’ (2005) 7 Nature Reviews 
Genetics 67-71. 
108 Genewatch, ‘Keeping blood spots from newborn babies’. 
109 Lysaught et al, “A pilot test of DNA-based analysis’, p.27 
110 Ibid. 
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raised issues of conflicts of interest,111 which requires robust policies and procedures 
to monitor. 
 
6.14 The involvement of commercial interests, while a reality, has raised public 
concern. One of those concerns is that “research funded or undertaken by 
commercial companies is likely to give priority to potential profits and to what can be 
patented than to public health.”112 
 
6.15 In the 2005 Public Consultation on the Storage and use of newborn babies 
blood spot cards (Oliver et al, IOE London) (final report not publicly available), 
commercial access to the UK blood spot collection was included as a question: Do 
you have any comments about commercial companies using blood spot cards to 
develop equipment or tests? Interestingly, there was no question about commercial 
access for research purposes. 
 
6.16 Evidence of public disquiet already exists. Dixon-Woods et al113 and Haddow 
et al114 have found that the attitudes of groups towards commercialisation can depend 
on their experience of ill-health. In particular, there can be marked differences 
between groups suffering from disease and their healthy counterparts both with 
respect to attitudes towards property claims and towards the prospect of others 
profiting from their contributions. Understandably, groups which have experienced ill-
health are usually very supportive of research and can be more tolerant of its 
commercial aspects than healthy groups. The prospect of profit might not be a 
stumbling block in itself, but rather the idea of excessive profit; this raises a 
further concern about exploitation – or perceptions of exploitation – all of 
which should be considered in robust access policies before any access is 
granted. 
 
II: Police Forensic Work 
6.17 There is also public concern is some quarters about the prospect of police 
access/use to genetic resources. The human rights ruling in S and Marper v UK is a 
case in point. Notwithstanding, it should be noted at the outset that the police can get 
access to any form of evidence, held in a medical context or otherwise, so long as 
lawful procedures are followed. The Guthrie collection is no different in this regard. It 
does not follow, however, that the prospect of police access should not be discussed 
or communicated openly with patients. We suggest that information material and 
access policies with respect to the police make this clear.  
 
6.18 Guthrie cards have been used by the police for two distinct purposes: to 
identify remains/deceased persons and for crime investigation. Two examples of the 
former use of Guthrie Cards are the identification of missing persons in the wake of 
                                            
111 GeneWatch, ‘Keeping blood spots from newborn babies’. 
112 Ibid., citing A. Harrison and B. New (2002), Public interest, private decisions: health-related 
research in the UK. London, The King’s Fund. 
113 M. Dixon-Woods et al, ‘Tissue samples an ‘gifts’ for research: a qualitative study of families and 
professionals’ (2008) 9 Medical Law International 131-150. 
114 Haddow et al, ‘Tackling community concerns’. 
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the tsunami in Sri Lanka,115 and the identification of deceased persons.116  While 
these uses are relatively uncontroversial, of greater concern is the use of Guthrie 
Cards for evidential purposes in crime detection and prosecution. Indeed, the 2003 
murder of Anna Lindh, Minister for Foreign Affairs in Sweden, in which a newborn 
blood spot card was used to positively identify the person suspected of the murder, 
created massive media attention and controversy.117 Similar police use led to the 
destruction of cards in Western Australia (para 2.21 above). In these instances, 
ethical considerations about protecting individual privacy often conflict with the 
provisions of the law; it is for this reason that procedures for police access need to be 
clear, and readily available to the public as well as those managing the resource.  
Once again, the distinction between the collection as information and the collection 
as tissue might have a bearing on the legal position. 
 
III: Obtaining information from health records for police use 
 
6.19 If Guthrie cards in Scotland are regarded as health records then guidance 
developed by the Scottish Government with the Association of Chief Police Officers 
on ‘Information sharing between NHS Scotland and the Police’118 is relevant.  In 
terms of access to information in a patient’s records, the Guidance provides the 
following: 
 
Type of request Action by Police Action by NHS Staff 
Written request for 
information from a 
patient’s medical record 
Police officer will provide: 
 Section 29 form to 
NHS or 
 Signed ‘consent’ 
form completed by 
subject of the 
inquiry 
NHS will provide 
information requested and 
retain Section 29 form, 
consent document 
Procurator Fiscal Request Procurator Fiscal will 
provide letter delivered by 
Police or Recorded Mail 
NHS will provide 
requested information and 
retain PF letter and 
completed incident 
reporting form in 
accordance with local 
procedures 
Sheriff Court Warrant Court will provide Sheriff’s 
Warrant delivered by 
Police or recorded Mail 
NHS will provide 
requested information and 
retain Warrant and 
completed incident 
reporting form in 
accordance with local 
procedures 
 
                                            
115 S.O. Hansson and B. Björkman, ‘Bioethics in Sweden’ (2006) 15 Cambridge Quarterly of 
Healthcare Ethics 285-203 at 287. 
116 See: ‘Privacy fears over method used to take Vicky’s DNA’, The Herald, 3 December 2008, p.16. 
117 Hansson and Björkman, ‘Bioethics in Sweden’, p.286. 
118 http://www.sehd.scot.nhs.uk/mels/CEL2008_13.pdf 
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6.20 The role of the ‘Section 29’ form in this procedure is, in effect, to make an 
official request for information.119 The police are not entitled to this information without 
an official warrant from a court of law, but the effect of the guidance is that it operates 
as an agreement on the part of NHS Scotland to accede to requests. This does not 
mean, however, that scrutiny procedures can be laid aside. Personnel within the 
NHS should act as gatekeepers with respects to such requests, and most 
notably and ideally Caldicott Guardians should be involved in all decisions.120 
Moreover, in circumstances in which there is doubt as to the legitimacy of a police 
request, a refusal would mean that a court warrant would have to be sought.    
 
IV: Obtaining samples for police use 
 
6.21 If the physical parts of the collection are seen as tissue in Scotland then, 
under the common law,121 a warrant would always be required.122 This reflects the 
position in England.123  
 
6.22 In England, the police require an access order to obtain samples for the 
purposes of a criminal investigation from existing collections held by third parties.  
Access orders may be sought by a constable pursuant to s.9(1) of the Police and 
Criminal Evidence Act 1984 (PACE) (which does not extend to Scotland) for ‘human 
tissue or tissue fluid which has been taken for the purposes of diagnosis or medical 
treatment and which a person holds in confidence’, provided certain conditions are 
met.124 
 
6.23 In Scotland, there is no statutory equivalent to the provisions in PACE for 
obtaining samples from third parties.  Legislation in Scotland, such as the Criminal 
Procedures (Scotland) Act 1995 (CPA), deals mainly with the taking of samples from 
arrested, detained or convicted persons (see for example ss.18 & 19 of the CPA).  In 
Scotland, powers of search and seizure are governed by the common law.  At 
common law, the police cannot enter a private premises without a warrant to search 
for evidence,125 unless consent has been given or in situations of urgency.126 The 
normal procedure is that police officers in Scotland who wish to obtain a search 
warrant make a report to the Procurator Fiscal who will then prepare the application 
                                            
119 The ‘Section 29’ form refers to section 29 of the Data Protection Act 1998, which provides that 
information can be disclosed without consent where failure to gain the information would be likely to 
prejudice: the prevention or detection of crime, the apprehension or prosecution of offenders, or the 
collection or assessment of any tax or duty. 
120 In the October 2007 minutes of the UK Council of Caldicott Guardians meeting, it was noted that, 
while the police in Scotland have a “standard form when requesting information from health 
organisations… this [does] not negate the need for [the] final decision to be made by the Caldicott 
Guardian”. 
121 See C.N. Stoddart, Criminal Warrants (2nd edn), (Edinburgh: Butterworths, 1999), p.63. 
122 This was the procedure in the Stephen Kelly case (unreported), in which the police seized personal 
medical information and a blood sample, which had been taken as part of a research project, with a 
warrant.  For information on the case see: C. Dyer, ‘Use of confidential HIV data helps convict former 
prisoner’, (2001) BMJ 322:633, and S. Connor, “Police access to medical data ‘a threat to research’’’, 
The Independent, 16 July 2001. 
123 See s.9 (1) of the Police and Criminal Evidence Act 1984 and Schedule 1. 
124 See: J. Kaye, ‘Police collection and access to DNA samples’, (2006) 2:1 Genomics, Society and 
Policy 16-27. 
125 Stoddart, Criminal Warrants, p.63. 
126 Ibid., p.133ff. 
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for a warrant to the appropriate magistrate, most commonly the Sheriff.127   Warrants 
to search premises must be specific as to the articles the search is intended to locate 
and the place(s) to be searched.  A warrant that is too wide and indefinite is illegal.128  
When carrying out a search under warrant in Scotland, police officers should follow 
what is considered ‘appropriate procedure’ in their area.129 
 
V: Missing persons 
 
6.24 With regard to the identification of missing or deceased persons, current 
practice in Scotland is that the police will obtain a letter from the Procurator Fiscal for 
release of the blood spot card.  
 
VI: Accessing children, parents and families 
 
6.25 The above analysis suggests that in the future it will be important to seek 
consent from parents or persons themselves about uses of the samples or data. 
Examples include where the proposed use exceed the bounds of what a reasonable 
citizen would expect, where a research use might be particularly controversial, where 
the sample or use involves identification of individuals and/or where an access or 
ethics committee otherwise deems consent to be necessary. In all such cases, the 
procedures for tracing and contacting people become very important. It is not 
acceptable, for example, for researchers simply to be given contact details in order to 
approach people ‘out of the blue’. Rather, approaches must be carried out sensitively 
and be proportionate in relation to the privacy implications. In such cases, it is 
important to identify a suitably-responsible intermediary to make the approach. This 
might be a senior official in National Services Scotland or National Registers for 
Scotland or from the Health Board under whose auspices the collection in held 
(Greater Glasgow & Clyde). Any approach should first be subject to ethical oversight 
by a suitable ethics committee or the Privacy Advisory Committee.     
 
POINTS TO CONSIDER AND RECOMMENDATIONS FROM CHAPTER 6:  
 
 A clear, robust and transparent access policy for the Guthrie collection 
in Scotland should cover all current and foreseeable future uses of the 
resource; 
 
 This policy should include guidance for decision-makers on relevant 
factors to take into account. This might include:   
 
o Determining the scientific or public value of the project;  
                                            
127 Ibid., p.9.  See also R. v. Manchester Stipendiary Magistrate and the Lord Advocate (Appellants) 
Ex Parte Granada Television Ltd. (Respondent) (On appeal from a Divisional Court of the Queen’s 
Bench Division) 14 December 1999, House of Lords, in which Lord Hope of Craighead stated that: 
‘When a constable of a Scottish police force wishes to obtain a search warrant he makes a report to 
the procurator fiscal, who in Scotland is the public prosecutor. This is because in Scotland applications 
to the courts of summary jurisdiction in criminal matters are made by the procurator fiscal, not by the 
police’. Available at: http://www.publications.parliament.uk/pa/ld199900/ldjudgmt/jd991214/granad-
1.htm 
128 Ibid., p.19. 
129 Ibid., p.69. 
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o Assessing ethical concerns both for individuals and society;  
o Establishing the pressing social need for the access;  
o Deciding whether consent can and should be sought for access;  
o Identifying any consequences of access for the resource; e.g. use 
of depletable samples, and  
o Implementing ways to minimise any adverse impact of the access;
 
 There should be mechanisms for prioritising research requests and 
requiring return of results to the resource in the spirit of benefit sharing; 
 
 A written protocol for the release of samples and information to the 
police be developed and made publicly available; 
 
 Personnel within the NHS should act as gatekeepers with respect to 
such requests, and most notably and ideally Caldicott Guardians should 
be involved in all decisions; 
 
 Given the existence of an opt-out system, consideration should be given 
to the mechanisms for adequately informing people about withdrawing 
consent if the person no longer wants the blood spot card to be used for 
research or other purposes; 
 
 Consideration should be given to the role of any Access Committee 
and/or oversight body in this regard (see further Chapter 7);  
 
 Those responsible for the collection must clearly define the purposes of 
the collection and link these to justifiable periods of retention; 
 
 Consideration needs to be given to the appropriateness of the actual 
physical environment in which the collection is held and the way in 
which it is archived; 
 
 Appropriate processes must be established for contacting people when 
seeking consent to use of samples and data.  
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CHAPTER 7: GOVERNANCE  
 
Key questions addressed by this chapter are: 
 
 Who is (or should be) responsible for the governance of the collection? 
 
  Who is legally liable if things go wrong?  
 
 Can existing oversight bodies, such as research ethics committees or 
the Privacy Advisory Committee, assist with the governance challenges 
of the Guthrie collection? 
 
 Can lessons be learned from other countries or other biomedical 
collections?  
 
 What does good governance look like? 
 
Key messages from this chapter are: 
 
 The relationship between the Glasgow Southern General Hospital – as 
immediate custodian of the initial sample collections for the first two 
years - and other entities such as Greater Glasgow & Clyde Health 
Board, National Services Scotland, NHS Research Scotland, and Health 
Improvement Scotland should be clarified within lines of accountability 
and framework for research governance. Ultimately, it is Greater 
Glasgow & Clyde Health Board that bears the responsibility of 
management of the collection but the input and influence of national 
bodies could be explained further.   
 
 Robust and transparent policies should be kept under constant review 
with respect to all aspects of the resource. Valuable lessons can be 
learned from the Danish model of research and access governance for 
newborn blood spot cards. 
 
 It is suggested that models used by UK Biobank and Generation 
Scotland to provide independent oversight of biomedical collections add 
considerable value in addressing the challenges of running a long-term 
resource into an uncertain future and could serve as possible models. 
Governance mechanisms for the Guthrie collection could learn useful 
lessons in this regard. 
 
 Governance mechanisms must include policies and procedures for 
raising awareness of the collection and engaging with the public and 
other stakeholders, such as the research community. 
 
 It is for consideration whether an education campaign like that 
envisaged by the Confidentiality and Security Advisory Group for 
Scotland (CSAGS) should now be undertaken in Scotland.
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DISCUSSION 
7.1 Good governance in healthcare has become a topic of significant interest in 
recent years. In the United Kingdom alone, numerous projects are underway with 
respect to information governance. Novel models of governance have been instituted 
for large-scale longitudinal genetic resource projects such as UK Biobank and 
Generation Scotland; the Scottish Health Informatics Programme (SHIP) has been 
launched with involvement of NHSScotland; the Ministry of Justice has published a 
report on Data Sharing and the UK Government has issued its response and Scottish 
Government has held various consultations on improving research infrastructure in 
Scotland and which culminated in the publication of its Guiding Principles for Data 
Linkage.130 A growing number of examples of good practice are emerging as lessons 
are learned from experience.131 In this regard, we should also consider foreign 
experiences, not just the cautionary such as those outlined in Chapter 2, but also the 
positive and especially that of the Danish Newborn Screening Biobank. In sum, there 
is much experience on which to drawn when considering the governance challenges 
of the Guthrie collection in Scotland. This chapter lays out those challenges as 
identified in this report and makes suggestions as to how these can be met. 
 
Governance challenges    
7.2 The following governance challenges face the Guthrie collection: 
 
 Although the Scottish Newborn Screening Laboratory sits under the auspices 
of Greater Glasgow and Clyde Health Board and NSS, it would be helpful to 
clarify how its operation should dove-tail with other branches of the work of 
NSS, such as Privacy Advisory Committee, and how/whether there should be 
a role for research ethics committees, for example in applications for access. 
The input from other agencies, such as NHS Research Scotland that has 
produced tissue research Guiding Principles, and Health Improvement 
Scotland, which is responsible for monitoring compliance under its 
Accreditation Scheme, further complicates matters. 
 
 More particularly, the role of the Caldicott Guardian with respect to the 
collection and the Scottish Newborn Screening Laboratory could be more 
explicit. 
 
 A Governance Board and/or an Access Committee has been established for 
the Guthrie collection and this is welcomed. Notwithstanding, its role and 
relationship to other bodies also needs further elucidation with respect to all of 
the points raised in previous chapters.  
 
                                            
130 At the time of writing this can be obtained on written request from 
Craig.Gilbert@scotland.gsi.gov.uk 
131 As an example from the Scottish Health Informatics Programme, see G. Laurie and N. Sethi, 
'Towards principles-based approaches to governance of health-related research using personal data' 
(2013) 4(1) European Journal of Risk Regulation 43-57.  
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 Independent oversight will be provided by Healthcare Improvement Scotland 
in monitoring the Guiding Principles. It is for further consideration whether this 
is sufficient for all aspects of the resource, especially given its potential high 
profile and public concerns that we discuss in the next chapter. Other large 
biomedical collections now benefit from such monitoring and advice.  
 
 There has been little effort to engage the wider public about the collection and 
its uses. Consideration should be given to the need for consultation. 
 
Learning from experience: Danish Newborn Screening Biobank (NBS-Biobank) 
7.3 This example has been chosen as the most closely analogous to the position 
in Scotland. Since 1982, residual dried blood spot samples from virtually all 
newborns in Denmark, Greenland and the Faroe Islands have been stored in the 
Danish Newborn Screening Biobank (NBS-Biobank). There are approximately 1.8 
million samples in the bank. 132  The purpose of the storage is: 
 
 Diagnosis and treatment of congenital disorders including documentation, 
repeat testing, quality assurance, statistics and improvement of screening 
methods; 
 Diagnostic use later in infancy after informed consent; 
 Legal use after a court order;  
 The possibility of research projects after approval by the Scientific Ethical 
Committee System in Denmark, the Danish Data Protection Agency and 
the NBS-Biobank Steering Committee.133  
Parents may “opt-out of biobank storage at the time of blood sampling by marking the 
data card, or at any time later, either by a written letter to the department or by 
registering in the central ‘Use of Tissue Register’ 
(www.Sundhedsstyrelsen.dk/vaev)”.134 
 
7.4 New Biobank Regulations were introduced in 2004 and incorporate the terms 
of the EU Data Protection Directive (which is also the basis of the Data Protection Act 
1998 in the UK). A Task Group on biobank regulation determined in 2002 that a 
biobank may be regarded as a ‘manual register’ and is, therefore, subject to the 
legislation in data protection. This provides some support for the Scottish 
position that Guthrie Cards are “medical records” and the conclusion in this 
report that they are subject to the Data Protection Act 1998. The Task Group 
also made recommendations which led to changes in the law: 
 
 The establishment of a central opt-out register for the use of tissue (the 
Central Use of Tissue Register), which allows people to opt-out of non-
treatment-related use of biological material, and a right to destruction or the 
conditional surrender of donated biobank material; 
                                            
132  See generally, B. Nørgaard-Pedersen and D.M. Hougaard, “Storage policies and use of the 
Danish Newborn Screening Biobank”, (2007) 30 Journal of Metabolic Disease 530-536. 
133 Nørgaard-Pedersen and Hougaard, “Storage policies and use of the Danish Newborn Screening 
Biobank”, p. 530. 
134 Ibid. 
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 The approval of all research projects using biobank material by a science-
ethical committee.135 
 
The new regulations on biobanks, published by the Ministry of Health in September 
2004, made the following provisions: 
 
1. The biobank and register must be registered and accepted by the Danish 
Data Protection Agency with information about purpose, operation, data-
responsible authority, biobank-responsible person, etc. (Act on processing 
of personal data).  The equivalent in the United Kingdom is the Information 
Commissioner’s Office. 
 
2. Accordance with the Act on Patients’ Rights which is concerned with ‘self-
determination’ for a clinical biobank concerning informed consent and the 
right to ‘opt out’, to ‘destruction’ or to ‘retrieval’ of the biobank material. 
There is no equivalent Act in Scotland or the United Kingdom, although the 
general legal position embodies a right to self-determination with a right to 
refuse.  
 
3. Procedures for use of biobank material for research must always be 
accepted by the Scientific Ethical Committee System according to the Act 
on Scientific Committee (www.cvk.im.dk). The Guthrie collection in 
Scotland currently has no such oversight. 
 
4. According to the Act on Health, the biobank-responsible person(s) is/are 
responsible according to general rules for personal health care concerning 
secrecy confidentiality, etc. Complaints concerning biobanks can be 
directed to the Health Care Patients Complaints Authority, Danish National 
Board of Health. As established above, the equivalent lines of 
accountability for the Scottish Guthrie collection lead to NSS within NHS 
Scotland.136 
 
Steering Committee for Scientific Use of the NBS-Biobanks 
7.5 A Steering Committee for Scientific Use of the NBS-Biobank (SCSU) was set 
up in 2005 to administer the use of the samples for research and, in particular, to 
prioritise the use of the residual blood spots to ensure that enough blood is left to 
serve the most important purposes, which are, first, the analysis of the residual blood 
spots for the benefit of the child and family and, second, the development of new 
methods for newborn screening analyses.137 
 
7.6 Once the proposed project has received approval from the Danish Data 
Protection Agency and the Scientific Ethics Committee System, the SCSU “evaluates 
the scientific value of the projects and the appropriateness of the proposed analytical 
technology”, ensuring that “there is always enough blood left of each sample to 
complete the necessary medical analyses directly related to the original purpose of 
                                            
135 Ibid. 
136 Ibid., p.532 
137 Ibid., p.533. 
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storage”, that being medical analyses for the benefit of the child and family.138 This is 
a very good example both of priority setting with respect to the use of a 
depletable resource and of robust mechanisms for assessing the 
scientific/public value of proposed uses. A further consideration for such a 
body might be an assessment of the likely privacy impact on individuals of 
granting any particular application for access and recommendations as to 
whether this is acceptable or might be minimised.   
 
7.7 In Scotland, the Greater Glasgow & Clyde Health Board Biorepository 
Governance Board acting as Access Committee could scrutinise applications in this 
way. Alternatively, or additionally, a research ethics committee or a body such as the 
Privacy Advisory Committee in Scotland could have such responsibility or even a 
wider oversight role. At the time of writing a consultation was underway on the need 
for a National Privacy Advisory Committee. In this respect, lessons might be learned 
closer to home from the UK Biobank project and the Generation Scotland project and 
existing guidelines/principles for tissue collections139.    
 
Learning from experience: UK Biobank and Generation Scotland 
 
7.8 The purpose of the UK Biobank project is to build a resource for research in 
the public good with the specific aim of improving the prevention, diagnosis and 
treatment of illness and promoting health throughout society. Recruitment took place 
between 2007 and 2010 and the resource now contains health and lifestyle data and 
biological samples from over 500,000 individuals aged 40-69 at time of enrolment. 
Participants give broad consent to participate in UK Biobank and grant permission to 
UK Biobank to access to their health records, provide some biological samples (e.g. 
blood and urine) and information about their lifestyle. The cohort will be followed up 
for decades, capturing all major health episodes and eventual death.  
 
7.9 UK Biobank operates within an Ethics and Governance Framework (EGF). 
The EGF is a public document which contains the express commitments of UK 
Biobank to its participants, to the public and to other stakeholders, such as 
researchers. The EGF affirms the right to withdraw at any time; makes a commitment 
to protect the confidentiality of both samples and data; confirms the role of UK 
Biobank as a steward of the resource (albeit, probably also its legal owner); 
describes the principles which will govern access to the resource and describes the 
benefit sharing arrangements that will be required of those who use the resource - 
these include the obligatory publication of findings (including negative results), return 
of data to UK Biobank, and the accessible storage of findings for future use.  
 
7.10 UK Biobank is monitored by the independent Ethics and Governance Council 
(EGC).140 The EGC is a permanent and independent body to oversee the project and 
to monitor and advise on its operation.141 Current challenges facing UK Biobank and 
the EGC are the development of access policy and procedures and the possible 
                                            
138 Ibid. 
139 e.g. SAHSC Bio-repository principles and Bio-repositories - Better Cancer Care.  
140 Laurie, the lead author of this report, was Chair of the Ethics and Governance Council (2006-10). 
141 UK Biobank Ethics and Governance Council: http://www.egcukbiobank.org.uk/ The Secretariat of 
the EGC is provided jointly by the Wellcome Trust and the Medical Research Council.  
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input of the EGC into the work of any Access Committee which might be established 
by UK Biobank.  
 
7.11 Generation Scotland (GS) has a similar scientific focus to UK Biobank in that it 
is concerned with gene/environment interaction in the onset of disease; it is entirely 
complementary, however, in that it seeks to recruit families and not unrelated 
individuals. GS also has governance parallels with UK Biobank in that it has been 
overseen by the Generation Scotland Advisory Board which performed a similar 
function to the UKB Ethics and Governance Council.142 This was disbanded in due 
course once the resource was firmly established, albeit the on-going issues continue 
to arise as access has got underway.  
 
7.12 In both cases, the rationale for an independent advisory body is related to the 
long-term nature of each project - which could extend for many decades - and the 
known unknowns surrounding the kinds of research that might be carried out using 
each resource and the kinds of researchers who will carry it out. Thus, such oversight 
bodies provide on-going scrutiny and input as the projects develop and change. This 
role has not been undertaken by any body to date in the UK with respect to life 
sciences research. Equally, Scotland must not succumb to the vagaries of 
unwarranted regulatory burden. What is important here is that the function, not 
necessarily the form, of such entities is built into governance arrangements. That is, 
these functions might be picked up by the Greater Glasgow & Clyde Biorepository 
Governance Board and there might be no need to establish a new one so long as the 
key features of this role are discharged.  
 
7.13 A further issue relates to the nature of the consent which is sought from 
participants and which arguably requires a different approach to that which has 
traditionally governed the involvement of individuals in research. This is broad 
consent as outlined above. This is used because it is not possible to give people full 
information prior to participation. Rather, the ethical (and legal) obligation is to inform 
people as the projects progress on matters such as access, research use, benefit 
sharing, commercialisation etc. In this way consent is constructed far more robustly 
as a process including an on-going obligation to engage with participants throughout 
the life of the project and not a one-off event prior to launch. Participants have a right 
to withdraw at any time and for any reason.   
 
The parallels here with the Guthrie collection should be self-evident. They require on-
going and robust engagement about the management and use of the Guthrie 
collection.  
 
Public engagement 
7.14 We address specific questions about public attitudes and engagement in the 
next chapter. Here we simply to point to the numerous junctures in this report, and in 
the experience of other collections, which suggest that a robust policy of public 
engagement is valuable and an increasingly essential feature of good governance. 
The English consultation on Guthrie cards contemplated the possibility of a public 
                                            
142 Laurie served as a member of the Generation Scotland Advisory Board. The Secretariat for the 
GSAB was provided by the Chief Scientist Office, Scottish Government.  
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scrutiny panel and regular public consultation exercise.143 At the time of writing the 
report remains unpublished. In Scotland, the Confidentiality and Security Advisory 
Group for Scotland (CSAGS)144 recommended in 2002 a public education campaign 
about uses of health information but no such campaign has taken place. We 
recommend that this issue be given serious reconsideration. 
 
POINTS TO CONSIDER AND RECOMMENDATIONS FROM CHAPTER 7:  
  
 While it is Greater Glasgow & Clyde Health Board that has the principal 
responsibility for governance of the Guthrie collection, the relationship 
with, and influence of, other entities such as National Services Scotland, 
NHS Research Scotland, and Health Improvement Scotland could be 
elucidated further.  
 
 Robust and transparent policies must be kept under review with respect 
to all aspects of the resource, especially because access requests are 
only likely to increase in the future. Valuable lessons can continue to be 
learned from the Danish model of research and access governance. 
 
 It is for consideration whether the Guthrie collection requires its own 
independent oversight body. The important feature, however, is not the 
form of this governance but the fact that the key features are 
incorporated into arrangements. Thus the NHS Greater Glasgow & Clyde 
Biorepository Governance Board might learn valuable lessons from 
existing independent bodies such as the UK Biobank Ethics and 
Governance Council.  
 
 Governance mechanisms must include policies and procedures for 
raising awareness of the collection and engaging with the public. 
 
 It is for consideration whether an education campaign like that 
envisaged by CSAGS should now be undertaken in Scotland. 
 
 
                                            
143 The report on the consultation document has not been made publicly available. 
144  http://www.sehd.scot.nhs.uk/publications/ppcr/ppcr.pdf 
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CHAPTER 8: PUBLIC ATTITUDES & PUBLIC ENGAGEMENT 
 
8.1 This chapter discusses some of the previous work that has been conducted on 
public attitudes to the storage and use of newborn bloodspots obtained for screening 
purposes.  Prior to 2009, there had been very little empirical work to examine the 
views of parents and the wider public on the possible research uses of these 
samples and associated information. However, as the scientific case for the research 
potential became more compelling, the associated social, ethical and legal issues 
remained to be characterised and solutions sought.  Empirical research exploring 
public attitudes is central to that endeavour as this will indicate whether or not there 
is broad public support, what public concerns are articulated and what conditions 
need to be met to ensure such support and alleviate concerns. Several studies, using 
both quantitative and qualitative research techniques, conducted in different 
countries, have helped answer key questions about what the public think about 
research uses of stored blood spots from newborn screening. The findings from 
studies in different jurisdictions, utilising different methods and with different 
participating population groups, while identifying a range of views, demonstrate 
overall support for the storage and use of these samples for research purposes, with 
appropriate safeguards and permissions. The results of several of these studies are 
distilled below and the key themes identified. The chapter then suggests what 
research, engagement and consultation should be conducted in Scotland to inform 
policy in this area. 
 
Key questions addressed by this chapter are: 
 
 What research has been conducted on public attitudes relating to the 
storage and use of newborn bloodspots? 
 What are the key findings from such research? 
 What needs to be done in Scotland to assess views and support public 
engagement? 
 
Key messages from this chapter are: 
 
 There seems to be majority support for the storage and future use of 
newborn bloodspots for health related research. 
 However, a minority do not support such use, with some evidence that 
this may be related to concerns about privacy, discrimination or lack of 
trust.   
 Overall, permission/consent was identified as essential for such support, 
although there are different views on when, how and what type of 
consent should be sought. 
 There is a lack of knowledge about retention and future use. Increased 
understanding was related to increased support in some studies. 
 Parents and the wider public wish to have information and choice. 
 Public engagement is likely to enhance trust and support for such 
biorepositories.  
 In the Scottish context, there should be a programme of public 
engagement to explore the public’s views and concerns and to identify 
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ways to promote on-going public involvement and the appropriate 
mechanisms for information sharing.  
 
Existing research on public attitudes 
Australia 
8.2 Davey et al (2005)145 conducted a survey of 600 new mothers in Perth, 
Western Australia, using a self-administered questionnaire.  This represented a 
response rate of 33%. The majority of women had heard of newborn genetic blood 
screening and over half were satisfied with the information provided.  However, some 
commented on the need for better information given at a more appropriate time.  
 
8.3 Twenty-nine per cent supported the current 2 year retention period and the 
same proportion a 3-10 year period.  However, the authors note that some women 
said that they did not know enough to make an informed answer; others thought that 
two years was enough to meet the primary purpose of the test.  Those supported a 
retention period of longer than 2 years seemed to be more keen on promoting 
research.  
 
8.4 Most (85%) believed that anonymised samples should be made available for 
research, with 4% disagreeing and 11% being unsure. More specific questions 
reaffirmed this commitment and also the strong concern about the need for samples 
to be de-identified.  Additional qualitative comments also identified the need for 
consent.   There was also support for different types of health related research. 
 
8.5 Survey research is of course limited by the questions asked and the scope 
provided for respondents’ answers.  Some of the question wording was rather 
positively framed (for example, respondents were asked the extent to which they 
agreed or disagreed with the statement: ‘I would like to have the opportunity to 
contribute positively to research through newborn screening cards’).   
 
8.6 Muchamore et al (2006)146 conducted qualitative research using moderated 
small group discussions in New South Wales.   Nine discussions were conducted 
with a total of 40 participants (24 women and 16 men) including young adults, 
parents with young children and parents with older children.  Each group met twice to 
allow a deliberative component.   
 
8.7 There was overall support for newborn screening although little specific 
knowledge.  Discussion of the retention and use of samples revealed little 
understanding that this occurred nor of why it might be useful.  The vast majority felt 
that parents should know that the dried blood spots were stored and could be used 
for a range of purposes.  
                                            
145 A. Davey, D. French, H. Dawkins and P. O’Leary P, ‘New mothers’ awareness of newborn 
screening, and their attitudes to the retention and use of screening for research purposes’ (2005) 1(3) 
Genomics, Society and Policy 41-51. 
146 I. Muchamore, L. Morphett and K. Barlow-Stewart, ‘Exploring existing and deliberated community 
perspectives of newborn screening: informing the development of state and national policy standards 
in newborn screening and the use of dried blood spots’ (2006) 3(14) Australia and New Zealand 
Health Policy: doi:  10.1186/1743-8462-3-14 
62 
 
8.8 Use for medical research was seen positively, but in the context of  parents 
being informed and consulted if identifying information was provided.  Parental 
consent was only seen as important by a few in the case of anonymised samples. 
There seemed to be a misconception that stored specimens might have direct future 
benefit to families.  
 
8.9 Views were expressed about unacceptable uses (e.g. research into human 
cloning; research that might lead to discrimination by insurers or employers) and 
about inappropriate access  - some felt concerned about  access by pharmaceutical 
and biotechnology companies because of the profit principle whilst others reflected 
on the need for such research (such findings resonate with Scottish research on 
public attitudes to Generation Scotland, Haddow et al 2007; 2008147).  Overall, the 
authors note a high level of trust in those representing the public good and therefore 
a  willingness for them to make decisions about appropriate research.  
 
8.10 Most saw value in stored samples being used to identify missing children and 
most were supportive of police access for solving crime.  However, amongst the 
groups of men, concern was expressed as there seemed to be general distrust of the 
police.  Concerns were also raised about security and privacy.   
 
New Zealand 
8.11 A comprehensive consultation has been undertaken in New Zealand, 
combining a public consultation with focus group research (Research New Zealand 
2007 a and b)148.  The consultation included closed and open ended answers to 
questions on information; consent; refusals; repeat sampling/testing; and storage and 
use. 182 responses were received with 80% of these being from private individuals 
(68% of whom were women).   
 
8.12 Focussing on the issue of storage, access and use, the consultation found that 
55% agreed with current New Zealand Police access to blood spot cards (to help 
identify a missing or deceased person or for other coronial inquiries within a 
Memorandum of Understanding between the Newborn Metabolic Screening 
Programme and the New Zealand Police).  A further 21% agreed but with some 
suggested changes and 19% disagreed with 5% either did not know or had no 
comment on this issue. Although this suggests majority support, nearly a fifth of 
respondents did not agree with the current policy.   
 
8.13 Forty-six per cent of respondents said that the blood spot cards should be 
stored indefinitely, 16% agreed with 21 years and 15% with 10 years.  Nineteen per 
cent suggested other time periods, ranging from three months to the average 
lifespan.  
                                            
147 G. Haddow, G. Laurie, S. Cunningham-Burley and K.G. Hunter, ‘Tackling community concerns 
about commercialisation and genetic research: A modest interdisciplinary proposal’ (2007) 64 Social 
Science and Medicine 272-282 and G. Haddow, S. Cunningham-Burley, A. Bruce and S. Parry, 
‘Generation Scotland: Consulting publics and specialists at an early stage in a genetic database’s 
development’ (2008) 18(2) Critical Public Health 139-149. 
148 K. Bendikson et al, ‘Newborn Blood Spot Cards: Consent, Storage and Use: A public consultation’,  
Research New Zealand, 18 December 2007.  
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8.14 Respondents were asked if they agreed or disagreed with the proposed 
process of approving research requests (formal approval by Ethics Committee and 
National Screening Unit).  Sixty-six percent agreed with the proposed approval 
process; 22% disagreed and 12% either did not know or had no comment.  Areas of 
concern amongst those disagreeing who provided comments were that the blood 
spots had not been originally taken for the purposes of research or that they 
(respondents) did not have enough knowledge of the organisations concerned.  
 
8.15 The focus group research involved seven groups of 37 participants of different 
ethnicities, including new parents and adults without children.  The research aimed to 
understand people’s perceptions and expectations about future storage and use of 
blood spot cards.  The research found support for screening but that attitudes and 
beliefs varied on some of the other issues.  None could recall, where relevant, 
receiving information about storage and future use.  There were a range of views 
about consent, although consensus about the need for consent. Some felt that there 
should be consent each time their child’s blood spot was being used, others felt that 
final consent at the time of screening was sufficient, so long as this included specific 
consent for storage and each possible future use.  The need for more information, 
given at an appropriate time and in an appropriate way, was also noted.   
 
8.16 Participants did not know that the blood spots were stored; this was an 
emotional issue for some due to the specific cultural meanings of blood amongst the 
Maori and Pacific peoples. The authors note that only some were comfortable with 
the idea of indefinite storage and the New Zealand Europeans expressed an 
attachment to their blood spots.   
 
8.17 Responses were also varied in relation to use of blood spots for research, with 
some happy about this and the proposed approval process and others concerned 
about lack of explicit consent or about final consent.  Other types of use, for example 
by police or for audit seemed to generate less concern.  
 
Canada 
8.18 Avard et al (2006)149 report on a consultative workshop held as part of a review 
of the social, ethical and legal issues regarding the storage, access and uses of 
newborn bloodspots.  The workshop included a range of participants:  policy makers, 
consumer groups, representatives from provincial NBS laboratories, health 
professional associations and the research community.   
 
8.19 In relation to uses of dried bloodspots, respondents were supportive of 
research but less supportive for other purposes, such as special family studies or 
forensic purposes.  It was noted: 
 
‘It was agreed that there may be appropriate and inappropriate 
secondary uses of newborn dried bloodspots although there was 
diversity on where to draw the line and how to proceed’ (p88) 
                                            
149 D. Avard, H. Vallance, C. Greenberg et al, ‘Variability in the storage and use of newborn dried 
bloodspots in Canada: Is it time for national standards?’ (2006) 2(3) Genomics, Society and Policy 80-
95. 
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8.20 Important factors raised were that secondary use should not interfere with the 
primary purposes of NBS; that identifiers must be removed and of course ethical 
approval gained.  However, concern was noted about whether research ethics 
boards were able to determine appropriate uses.   Most felt that future use for 
forensic purposes was a violation of individual liberties. 
 
8.21 The workshop found no consensus over whether informed consent should be 
obtained before secondary use for research purposes took place. However, many 
seemed to think that if samples were anonymised and the research subject to ethical 
review, then explicit consent should not be required.  Further research might help 
illuminate whether explicit consent should be required or assumed, but that the issue 
would remain complex. For example, would the primary purpose be negatively 
affected if consent for future use was required but then would individual autonomy 
and privacy rights be compromised if explicit consent was not obtained? Participants 
also noted that parents need to be informed about storage and future use as well as 
about the screening programme more generally.  
 
8.22     Bombard et al (2012)150 explored citizens’ values about research with stored 
samples from newborn screening. Focus groups with an educational component, 
deliberative discussion and a pre and post interview questionnaire were employed. 
The study focussed on anonymous medical research and linkage to other 
information, as this reflects the approach in Canada as well as elsewhere. 
 
8.23      The study found overall support for future anonymous research, with 90% 
(36 participants) agreeing to storing samples for such use and further support 
identified in the focus groups.  Most suggested the need for choice in relation to 
whether their child’s sample should be stored, although some thought that parents’ 
should be required or at least strongly encouraged to allow such storage and use. 
 
8.24     The researchers identified three key themes that underlay these differences:  
level of trust, concern about harms and where the balance between individual and 
population interests lay.  
 
8.25   There was strong agreement that parents need to be informed about the 
secondary use of newborn bloodspots. 
 
8.26  Given the differences between participants in relation to parental choice, the 
authors conclude that: 
 
Ultimately, although public engagement exercises may elucidate 
values, enhance transparency, and inform policy, they may not 
necessarily provide explicit policy direction (p245)    
     
 
 
                                            
150 Y. Bombard, F.A. Miller, R. Hayeems et al, ‘Citizens’ values regarding research with stored 
samples from newborn screening in Canada’ (2012) 129 Pediatrics 239-247. 
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USA 
8.27    There have been several studies in the USA over the past few years exploring 
public attitudes.  These have included different States and diverse methods and 
populations.  The first are a group of publications by a research team including Botkin 
and Rothwell from the University of Utah.  
8.28   Botkin et al (2012)151 conducted a multi-method study utilising a survey 
(paper/telephone), focus groups and an internet survey through Knowledge Network 
panels.  A total of 3855 participants were involved in these studies.  An educational 
movie or written information was provided.  
8.29   Although the study found strong support for NBS, 30% of survey respondents 
indicated that they were very concerned about retention.  Those with lower concern 
were more likely to have seen the movie rather than the written information, to be 
white, a mother of young children, with higher educational attainment and to have 
been surveyed by telephone.  
8.30   However, there was majority support (80%) for potential uses of residual 
bloodspots whether this was for quality control, research on diseases affecting 
mothers and children or research on diseases of the general population.  
8.31   The survey asked whether an opt-in or opt-out permission model was 
preferred. 62% supported an opt-in model.  The factors that were associated with 
selecting an opt out model were movie education, older age and higher  level of 
education. 
8.32  This study reinforced the importance of providing information; this led to 
increased support as well as improving knowledge.  The authors note that their focus 
group discussions demonstrated that participants were supportive of retention but 
wanted more information and that choice was important.  
8.33   Rothwell et al (2012)152 report on the focus group element of the above study.  
Fourteen groups were conducted across six states, with a total of 128 participants.  
The groups included ones with the general population, African-American groups, 
Hispanic groups and mothers with young children. 
8.34   The results suggest support for the retention and use of residual blood spots 
for research. There was a preference for an opt-in approach although some 
recognition of the logistical issues with this. 
8.35   There was general support for research to improve health or provide medical 
benefit if conducted by university or medical departments rather than pharmaceutical 
companies.  
                                            
151 J.R. Botkin, E. Rothwell, R. Anderson et al, ‘Public attitudes regarding the use of residual newborn 
screening specimens for research’ (2012) 129 Pediatrics 231-238. 
152 E. Rothwell, R. Anderson, A. Goldenberg et al, ‘Assessing public attitudes on the retention and use 
of residual newborn screening blood samples: a focus group study’ (2012) 74 Social Science and 
Medicine 1305-1309. 
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8.36  Personal control was considered important with participants expressing their 
right to choose, their need to be informed and to be able to change their minds.  
8.37  Rothwell’s earlier study (2010)153 also employed focus group methods, with 
three groups, an African American group, a Paediatrician group and a Mothers of 
young children group.   They noted that that guidance had tended not to be informed 
by public input and suggest this is a failure than could become problematic.  
8.38  This research identified the need for informed consent on both anonymous and 
identifiable residual samples, appropriate ethical review, consent for storage, fears of 
discrimination arising from research and lack of awareness of the programme.  
8.39   Duquette and colleagues at Michigan Department of Community Health and 
University of Michigan report on two studies.  The first comprised a set of four 
questions on the 2008 Behavioural Risk Factor Surveillance System (telephone 
survey)154.  These asked about support for the use of dried blood spots for research 
in general, for specific diseases (general health research, childhood, adult and 
environmental exposure).  The sample was 3018 adults. 
8.40 The majority (72.3%) supported the use of dried blood spots for research; those 
who were female, younger, white, healthy and with at least a high school degree 
were more likely to say that they were in favour.  Only three per cent strongly 
opposed.   
8.39    Support was high for each type of use with little variation across use; indeed it 
was higher than for the overall question about use.  This support was associated with 
age, education and household income.   
8.41   The second study reported by Duquette et al (2010) involved ten focus groups 
from diverse communities.  The discussions explored public views about the 
Michigan BioTrust for Health, a program for storage and use of residual newborn 
screening dried blood spots: 
‘Community engagement was considered critical for assuring that 
samples are used in a manner acceptable to the public and to the 
ultimate success of the MDCH BioTrust initiative’ (p147)  
8.42   Four key questions were used focussing on initial thoughts about the BioTrust, 
types of research that would be acceptable, how consent should be obtained and 
how you would feel about your own or your child’s de-identified blood spots being 
used for research.  Each participant was provided with written information, there was 
a presentation and a pre and post survey. 
8.43   There was very strong support for the idea of a BioTrust, with none saying they 
were opposed and a consensus being reached.  The survey produced consistent 
results, with 86.4% strongly or somewhat agreeing. There was also broad support for 
                                            
153 E. Rothwell, R.N. Anderson, J. Botkin, ‘Policy issues and stakeholder concerns regarding the 
storage and use of residual newborn dried blood samples for research’ (2010) 11(1) Policy, Politics & 
Nursing Practice 5-12. 
154 D. Duquette, A.P. Rafferty, C. Fussman et al, ‘Public support for the use of newborn screening 
dried blood spots in health research’ (2010) 14 Public Health Genomics 143-152. 
67 
any type of health research, although participants identifying cloning or cosmetic 
research as exceptions.  The post discussion survey identified increased support.  In 
the survey, support for use by academic institutions was higher than for private 
sectors, but in the focus groups there was a recognition that distinguishing these two 
was sometimes difficult and the type of research seemed to be more important than 
who was conducting it.  
8.44    There was a consensus that information was required for informed decision 
making but different views as to how this might be provided. There was also lack of 
consensus in the focus groups about whether consent should be opt-in or opt-out.  
This was reflected in the survey responses also.  
8.45  Lastly, there was general agreement about using one’s own or one’s child’s 
bloodspots in de-identified research.  In the questionnaires, willingness increased 
post discussion.  Privacy concerns were expressed by a minority and opinion was 
divided about the benefit of receiving research results.  
8.46  Tarini et al’s research155 comprised an internet survey of a nationally 
representative sample of parents, with a sample size of 1508.  This examined 
willingness to permit use of their children’s newborn samples and to allow storage.  
8.47    Overall, 76.2% responded that they were willing or somewhat willing to permit 
use, with permissions.  This dropped to 28.2% if permission was not obtained  
Seventy-eight per cent would permit storage; those less willing to permit use were 
also less willing to permit storage.   
8.48   They conclude that it is important to: 
‘engage the public in a transparent and informative discussion that 
also provides parents a forum in which to voice their concerns.’ 
(p129) 
8.49   Neidich et al (2010)156  conducted a survey of women in University of Chicago 
hospitals who had live infants.  239 women participated, with 82% self-classifying as 
black.  The researchers wanted to explore attitudes to a hypothetical paediatric 
biobank as a response to ethical concerns about a proposed programme, particularly 
what additional safeguards might be required and what information beyond the usual 
consent requirements.  
8.50   The results suggested some support for such a biobank, with 48% of women 
saying they’d be willing to enrol their child and 28% being not sure.  Caucasians were 
the most willing.  
8.51  The research also explored why people responded as they did and 58% 
expressed altruism for societal benefit.  Exploring what that benefit might be, the 
survey contained questions about trust and justice. Understanding of research, trust 
                                            
155 B.A. Tarini, A. Goldenberg, D. Singer et al, ‘Not without my permission:  Parents’ willingness to 
permit use of newborn screening samples for research’ (2010) 13 Public Health Genomics 125-30. 
156 A.B. Neidich, W.J. Josh, C. Ober and L.F. Ross, ‘Empirical data about women’s attitudes towards a 
hypothetical pediatric biobank’ (2010) American Journal of Medical Genetics Part A: 297-304. 
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in researchers and a belief that findings would be used fairly all correlated with 
hypothetical enrolment. The authors conclude that: 
‘It is imperative that researchers help ensure that the women’s 
trust and justice beliefs are fulfilled’ (p303) 
China 
8.52   Gong and colleagues conducted the first survey of Chinese parents regarding 
the use of newborn screening samples.  This was a hospital-based survey to explore 
attitudes to newborn screening sample storage and permitting use for research (with 
or without consent).  With a 52% response rate, the sample size was 378.  The 
research was conducted in Beijing.  
8.53   Sixty-eight per cent of parents would permit infants’ samples to be stored but 
this dropped to 14% if no permission was obtained.  This did not seem to be 
explained  by a range of socio-demographic variables, such as gender, education or 
household income. Those who would not approve of use in those circumstances also 
reported that they should be given more information: 
‘They strongly believed that they – and not merely the researchers 
– should play a more important role in such research’ (p191) 
8.54  Although these authors note similarities between their findings and other 
research such as that summarised above, they also suggest that there is a basic lack 
of trust between patients and doctors in China and therefore concern about rights 
and privacy.  
Japan 
8.55  Fujii et al (2010)157 conducted a questionnaire study to examine the attitudes of 
the public, parents, patient families and health professionals to extended uses of 
newborn screening and storage of blood spots.  They found that awareness of 
newborn screening was low amongst the general public and they were less likely to 
be positive about the extended use for the study of health problems. Patient families 
and health professionals were more positive.  
8.56 The open ended comments were analysed through text mining and three 
concepts were identified: personal data (for example, privacy); consent availability; 
and progress in medical science.  As with other studies, they noted the importance of 
information. 
England 
 
8.57 Research by Hargreaves et al (2005)158 from the Parent Support Research 
Team of the UK Newborn Screening Programme Centre touched on this issue. 
Hargreaves et al conducted a qualitative study involving telephone interviews and 
                                            
157 C. Fujii, Y. Sato, S. Harada et al ‘Attitudes to extended use and long-term storage of newborn 
screening blood spots in Japan’ (2010) 52 Pediatrics International 393-397. 
158 K. Hargreaves, R.J. Stewart and S.R. Oliver SR, ‘Informed choice and public health screening for 
children: The case of blood spot screening’ (2005) 8 Health Expectations 161-171. 
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focus groups with 47 parents and 35 health professionals.  They found that amongst 
some parents the need for written consent was heightened when the storage of 
bloodspots was considered.  
 
Conclusions on public engagement 
 
8.60  Research across different jurisdictions, using different methods identify overall 
support for the storage and research use of newborn blood spots.  However, some 
are less supportive and support is contingent on a number of factors. Consent, 
control, trust and information are all identified as key to maintaining and promoting 
public support.  
 
8.60  In policy terms, the research is clear about the need for public engagement, not 
as a one-off consultation to ascertain views but as an integrated component of the 
on-doing relationship between citizens and those who procure, curate and use 
newborn blood spot collections.   This suggests an approach to engagement that 
embraces awareness raising, consultation and empowerment. 
 
8.61  Research and public engagement should be conducted in Scotland to explore 
views and attitudes as well as to shape best practice in public involvement in 
governance.  
 
 
 
 Although previous research on public and professional attitudes does 
not suggest widespread distrust or concern about the storage and use of 
newborn bloodspots, the issues of consent, access, appropriate use and 
regulation are pertinent and there is a degree of ambivalence about 
appropriate policies.  This needs to be resolved transparently and with 
public input.  
 
 We recommend primary research on public and professional attitudes 
and concerns about the storage and further use of newborn bloodspots 
and a programme of public and stakeholder engagement for effective 
governance. 
POINTS TO CONSIDER AND RECOMMENDATIONS FROM CHAPTER 8 
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CHAPTER 9 - SUMMARY OF POINTS, RECOMMENDATIONS AND 
FUTURE CONSIDERATIONS  
 
General considerations 
 It is essential to consider the full range of people affected by the collection. 
Different people might be affected in different ways and different legal rules 
might apply to them.  
 
 It is essential to consider the full range of purposes for which the collection 
might be used both now and in the future. Although a range of purposes might 
be justified, the case for each use must be clearly made.  The justifications 
must be stronger as the use becomes more about the public interest and less 
about each person’s health interest.  
 
 It is essential that clear, transparent and robust policies are in place for every 
aspect of the collection from initial taking of consent and samples, to storage, 
quality assurance, access and contingency planning. While many aspects of 
the collection are now covered in this respect, all policies must be kept under 
regular review given the rapidly changing social and scientific landscape.   
 
Legal Basis 
 The Guthrie collection should be treated as both personal information and 
human tissue for the purposes of legal governance.  
 
 The existing collection is lawful but careful attention must be paid to matter of 
future use and access. 
 
 Consent to use is not an absolute requirement but should not be departed 
from lightly.  
 
 Anonymisation can remove some legal obligations but not all obligations; 
moreover, it is not a complete answer to the challenges thrown up by the 
collection. 
 
 Human rights are a consideration across all areas of law. All mechanisms, 
policies and procedures should be tested for human rights compliance. 
 
Consent and anonymisation 
 The law does not require that specific consent be sought from all persons 
whose samples or data are held in the Guthrie collection; it is for consideration 
none the less, whether such consent should be sought as a matter of good 
practice. 
 
 If specific consent is not sought, all the more emphasise must be placed on 
the system of opt-out that exists. This is the principal means to respect 
persons whose samples/data are contained in the collection. It requires clear 
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communication to the public about uses of the collection and details about the 
governance mechanisms in place. Vitally, citizens must be able to know easily 
how to exercise their right to opt-out and have the respected in a timely 
fashion.  
 
 Because people consent to inclusion in the collection on the basis of broad 
consent, attention should be given to how they will be kept up-to-date with 
uses of the resource as and when these occur. 
 
 It is for consideration whether a system of ‘consent for consent’ should be 
considered to facilitate access to the Guthrie collection for research purposes; 
caution should be exercised, however, about adopting a presumed consent 
approach. 
 
 Specific consent should be sought from individuals if access is contemplated 
for non-standard purposes, e.g. non-health-related research. 
 
 It is for consideration whether mature minors should be allowed to opt-out of 
the collection. 
 
 Procedures should be developed for circumstances where access will be 
given without consent but subject to suitable authorisation. 
 
 Procedures should be developed to decide whether and how access will be 
granted if neither consent nor anonymisation is possible. 
 
 Consideration should be given to scrutiny mechanisms authorising access 
even when anonymisation is contemplated. 
 
 A policy should be developed on whether and how feedback of individual 
results will be given. 
 
 A decision should be taken on Open Access to the resource or results from 
the resource. 
 
 A Privacy Impact Assessment should be carried out on the Guthrie collection. 
 
Storage and access 
 A clear, robust and transparent access policy should be kept under regular 
review for the Guthrie collection in Scotland to cover all current and 
foreseeable future uses of the resource;  
 
 This policy should include guidance for decision-makers on relevant factors to 
take into account. This might include:   
 
o scientific or public value of the project;  
o ethical concerns both for individuals and society;  
o the pressing social need for the access;  
o whether consent can and should be sought for access;  
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o any consequences of access for the resource; e.g. use of depletable 
samples, and  
o ways to minimise any adverse impact of the access. 
 
 There should be some mechanism for prioritising research requests; 
 A written protocol for the release of samples and information to the police be 
developed and made publicly available; 
 If an opt-out system is thought to be desirable, consideration should be given 
to the mechanism for withdrawing consent if the person no longer wants the 
blood spot card to be used for research or other purposes.  
 Consideration should be given to the role of an Access Committee and/or 
oversight body in this regard. 
 
Governance 
 The relationship between the Yorkhill Centre and NSS should be clarified 
within lines of accountability and framework for research governance. In 
particular, what is the relationship with:  
 
 Robust and transparent policies should be development with respect to all 
aspects of the resource. Valuable lessons can be learned from the Danish 
model of research and access governance for newborn blood spot cards. 
 
 It is for consideration whether the Scottish Guthrie collection requires its own 
Governance Board and/or Access Committee. 
 
 It is for consideration whether the Guthrie collection requires an independent 
oversight body. It is recommended that models used by UK Biobank and 
Generation Scotland add considerable value in addressing the challenges of 
running a long-term resource into an uncertain future and could serve as 
possible models. 
 
 Any governance mechanisms that are instituted must include policies and 
procedures for raising awareness of the collection and engaging with the 
public. 
 
 It is for consideration whether an education campaign like that envisaged by 
CSAGS should now be undertaken in Scotland. 
 
Public attitudes and public engagement 
 Previous research on public and professional attitudes does not suggest 
widespread distrust about the storage and use of newborn bloodspots but 
some degree of ambivalence was expressed by some. 
 
o the Caldicott Guardian,  
o Research ethics committees and  
o Privacy Advisory Committee?  
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 The issues of consent, access, appropriate use and regulation are relevant to 
parents and a variety of opinions are expressed about appropriate 
mechanisms.   
 
 We recommend primary research on public and professional attitudes and 
concerns about the storage and further use of newborn bloodspots and a 
programme of public and stakeholder engagement for effective governance 
and policies. 
 
Future considerations 
 
The essential issue at the heart of all challenges relating to biomedical collections 
such as the Scottish Guthrie card collection is the question of time. The Guthrie 
collection was started at a time when ethical and social expectations were very 
different to those of today. Its potential value has become clearer over time and 
this forms the basis for arguments in favour of its retention; equally, only time will 
tell which kinds of request for future uses might arise and whether these will be 
granted. It is also very likely that public and individual expectations and attitudes 
will change. It would be unhelpful and unproductive to attempt to respond to 
speculative Frankenstein futures that can be imagined by the advent of 
developments such as cloud computing and genome-wide association studies. 
There is little doubt that the potential of biomedical collections will only increase, 
but we cannot say today what will be the appropriate responses of tomorrow. 
Notwithstanding, all of this speaks to the important of dynamic and robust 
governance that can respond to near-future challenges of storage, management 
and use as and when they arise. Given the cross-cultural and wide-ranging 
disciplinary issues at stake, it will be important to provide ample manoeuvre in 
developing appropriate responses to technological advances and which take into 
account the implications for science and society. For these reasons, as a final 
recommendation we suggest that jointly-funded AHRC and ESRC doctoral 
scholarships be pursued to examine the cross-cutting themes.  
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